var valueQuestionVariables =  [];


    var rulesJson = [{"target":"3bcc2a94-6dda-4063-8bd4-f124b9615cf7","source":"a4973daf-fc93-41d0-b7fd-cd6faaecc9bb","label":"","guId":"1daf98c4-1301-4718-aca6-e7618356e099","targetRule":"fa0951ac-8a06-4d2b-88f9-27d4d4234bea"},{"target":"1bd28e57-e5a0-4217-8feb-04bbce28327e","source":"3bcc2a94-6dda-4063-8bd4-f124b9615cf7","label":"","guId":"fa0951ac-8a06-4d2b-88f9-27d4d4234bea","targetRule":"4c7643cc-1625-479b-a69d-27a5532853d7"},{"target":"f8e8f960-6d9d-4808-8a4a-b3c6ef8deaf6","source":"1bd28e57-e5a0-4217-8feb-04bbce28327e","label":"","guId":"4c7643cc-1625-479b-a69d-27a5532853d7","targetRule":"b5c0d4e3-ee7f-46f7-bead-98c66840f44a"},{"target":"080a7c12-227e-41e5-9248-d49500f9a13f","source":"f8e8f960-6d9d-4808-8a4a-b3c6ef8deaf6","label":"True","guId":"b5c0d4e3-ee7f-46f7-bead-98c66840f44a","targetRule":"cd59cff6-4b97-469d-97ba-a3f3117f3331"},{"target":"080a7c12-227e-41e5-9248-d49500f9a13f","source":"f8e8f960-6d9d-4808-8a4a-b3c6ef8deaf6","label":"False","guId":"b5c0d4e3-ee7f-46f7-bead-98c66840f44a","targetRule":"ecac9c52-1c79-4edf-b3f8-2c6b82360f23"},{"target":"f5175785-b752-4647-9fea-9f0d614dd6b4","source":"080a7c12-227e-41e5-9248-d49500f9a13f","label":"VKA","guId":"cd59cff6-4b97-469d-97ba-a3f3117f3331","targetRule":"64b3e88d-f5d7-4c22-898d-c2631d3e13ce"},{"target":"1983119e-7c6c-4fb4-bc43-4a4d4757c01c","source":"080a7c12-227e-41e5-9248-d49500f9a13f","label":"DOAC","guId":"cd59cff6-4b97-469d-97ba-a3f3117f3331","targetRule":"82ba19cb-90c2-4875-91d7-e305053bf6d7"},{"target":"d359bcfb-7c8f-40a0-9d84-6bb443a478a8","source":"f5175785-b752-4647-9fea-9f0d614dd6b4","label":"3b. No","guId":"64b3e88d-f5d7-4c22-898d-c2631d3e13ce","targetRule":"1735e312-9551-4b1f-810d-049f15bf8182"},{"target":"d359bcfb-7c8f-40a0-9d84-6bb443a478a8","source":"f5175785-b752-4647-9fea-9f0d614dd6b4","label":"3a. Yes","guId":"64b3e88d-f5d7-4c22-898d-c2631d3e13ce","targetRule":"8bbef52b-63b1-448b-a432-8374e1f9f476"},{"target":"25985631-5b37-4b29-8865-b0644767b4e4","source":"d359bcfb-7c8f-40a0-9d84-6bb443a478a8","label":"","guId":"1735e312-9551-4b1f-810d-049f15bf8182","targetRule":"a9a13f67-254b-4b23-9914-714ce4d129ce"},{"target":"63546ecf-79d8-4e3e-b48f-4b550266132a","source":"25985631-5b37-4b29-8865-b0644767b4e4","label":"","guId":"a9a13f67-254b-4b23-9914-714ce4d129ce","targetRule":"347e698c-72ef-4530-b43a-343b394a0a6c"},{"target":"54106970-b317-4119-86d8-f10e1e5be15b","source":"63546ecf-79d8-4e3e-b48f-4b550266132a","label":"","guId":"347e698c-72ef-4530-b43a-343b394a0a6c","targetRule":"6339d263-2df8-49c9-be65-9ff5926310b6"},{"target":"7ccad62c-279b-4af2-8239-a584e5ed01b8","source":"54106970-b317-4119-86d8-f10e1e5be15b","label":"","guId":"6339d263-2df8-49c9-be65-9ff5926310b6","targetRule":"c494a07d-307b-480b-933c-26ea1c0940ef"},{"target":"","source":"7ccad62c-279b-4af2-8239-a584e5ed01b8","label":"","guId":"c494a07d-307b-480b-933c-26ea1c0940ef","targetRule":"e204e835-be37-4448-b76e-5cc679e29653"},{"target":"25985631-5b37-4b29-8865-b0644767b4e4","source":"d359bcfb-7c8f-40a0-9d84-6bb443a478a8","label":"","guId":"8bbef52b-63b1-448b-a432-8374e1f9f476","targetRule":"540e1dd6-e8bc-4579-88f9-14c4099d4622"},{"target":"cda60017-1bab-476c-b30b-393c32c592dd","source":"25985631-5b37-4b29-8865-b0644767b4e4","label":"","guId":"540e1dd6-e8bc-4579-88f9-14c4099d4622","targetRule":"9522ff71-d63e-48fc-b329-846ce0a215e6"},{"target":"54106970-b317-4119-86d8-f10e1e5be15b","source":"cda60017-1bab-476c-b30b-393c32c592dd","label":"","guId":"9522ff71-d63e-48fc-b329-846ce0a215e6","targetRule":"6339d263-2df8-49c9-be65-9ff5926310b6"},{"target":"d359bcfb-7c8f-40a0-9d84-6bb443a478a8","source":"1983119e-7c6c-4fb4-bc43-4a4d4757c01c","label":"Betrixaban","guId":"82ba19cb-90c2-4875-91d7-e305053bf6d7","targetRule":"4783b361-9788-48cb-afde-92b3cbfdd10f"},{"target":"d359bcfb-7c8f-40a0-9d84-6bb443a478a8","source":"1983119e-7c6c-4fb4-bc43-4a4d4757c01c","label":"Rivaroxaban","guId":"82ba19cb-90c2-4875-91d7-e305053bf6d7","targetRule":"4783b361-9788-48cb-afde-92b3cbfdd10f"},{"target":"d359bcfb-7c8f-40a0-9d84-6bb443a478a8","source":"1983119e-7c6c-4fb4-bc43-4a4d4757c01c","label":"Dabigatran","guId":"82ba19cb-90c2-4875-91d7-e305053bf6d7","targetRule":"bf61481c-fd43-45d4-9eb8-136af1320490"},{"target":"d359bcfb-7c8f-40a0-9d84-6bb443a478a8","source":"1983119e-7c6c-4fb4-bc43-4a4d4757c01c","label":"Apixaban","guId":"82ba19cb-90c2-4875-91d7-e305053bf6d7","targetRule":"4783b361-9788-48cb-afde-92b3cbfdd10f"},{"target":"d359bcfb-7c8f-40a0-9d84-6bb443a478a8","source":"1983119e-7c6c-4fb4-bc43-4a4d4757c01c","label":"Edoxaban","guId":"82ba19cb-90c2-4875-91d7-e305053bf6d7","targetRule":"4783b361-9788-48cb-afde-92b3cbfdd10f"},{"target":"6783018b-9eef-4507-9c10-5b5d150d0f57","source":"d359bcfb-7c8f-40a0-9d84-6bb443a478a8","label":"","guId":"4783b361-9788-48cb-afde-92b3cbfdd10f","targetRule":"1e301651-b612-408a-863b-a2a3d9dc2ca5"},{"target":"f5175785-b752-4647-9fea-9f0d614dd6b4","source":"6783018b-9eef-4507-9c10-5b5d150d0f57","label":"","guId":"1e301651-b612-408a-863b-a2a3d9dc2ca5","targetRule":"7d7aa155-fcd0-4a9c-a1bd-a6ca0a0dbb26"},{"target":"1983119e-7c6c-4fb4-bc43-4a4d4757c01c","source":"f5175785-b752-4647-9fea-9f0d614dd6b4","label":"3a. Yes","guId":"7d7aa155-fcd0-4a9c-a1bd-a6ca0a0dbb26","targetRule":"23d2e637-65d2-4ba0-89d7-a7253a4360c0"},{"target":"1983119e-7c6c-4fb4-bc43-4a4d4757c01c","source":"f5175785-b752-4647-9fea-9f0d614dd6b4","label":"3b. No","guId":"7d7aa155-fcd0-4a9c-a1bd-a6ca0a0dbb26","targetRule":"42041ed5-6526-4344-959d-042eaa32a4da"},{"target":"a5e51e81-2ae1-4b43-b571-f0ade0be38a7","source":"1983119e-7c6c-4fb4-bc43-4a4d4757c01c","label":"Rivaroxaban","guId":"23d2e637-65d2-4ba0-89d7-a7253a4360c0","targetRule":"a04c9cad-f754-4143-a14f-f1a4ab557841"},{"target":"9e7e9da0-e3a6-4977-8a86-05b32c2a925b","source":"1983119e-7c6c-4fb4-bc43-4a4d4757c01c","label":"Apixaban","guId":"23d2e637-65d2-4ba0-89d7-a7253a4360c0","targetRule":"c36fa1ef-5b14-4b16-8f36-f00fd82e90eb"},{"target":"7f9fdbb2-2bcf-4d1b-ae1b-503472cc6ba5","source":"1983119e-7c6c-4fb4-bc43-4a4d4757c01c","label":"Betrixaban","guId":"23d2e637-65d2-4ba0-89d7-a7253a4360c0","targetRule":"d4797b1d-5ea8-4f31-a801-2dba5bd6bb6e"},{"target":"7f9fdbb2-2bcf-4d1b-ae1b-503472cc6ba5","source":"1983119e-7c6c-4fb4-bc43-4a4d4757c01c","label":"Edoxaban","guId":"23d2e637-65d2-4ba0-89d7-a7253a4360c0","targetRule":"d4797b1d-5ea8-4f31-a801-2dba5bd6bb6e"},{"target":"54106970-b317-4119-86d8-f10e1e5be15b","source":"a5e51e81-2ae1-4b43-b571-f0ade0be38a7","label":"","guId":"a04c9cad-f754-4143-a14f-f1a4ab557841","targetRule":"2e60abd8-e73d-440e-b53d-5f1f1a3cf359"},{"target":"7ccad62c-279b-4af2-8239-a584e5ed01b8","source":"54106970-b317-4119-86d8-f10e1e5be15b","label":"","guId":"2e60abd8-e73d-440e-b53d-5f1f1a3cf359","targetRule":"6e047e25-7457-4902-9e51-4ff6f178ad5b"},{"target":"","source":"7ccad62c-279b-4af2-8239-a584e5ed01b8","label":"","guId":"6e047e25-7457-4902-9e51-4ff6f178ad5b","targetRule":"3a975bbe-e9c3-4b67-80ef-f4766dade825"},{"target":"54106970-b317-4119-86d8-f10e1e5be15b","source":"9e7e9da0-e3a6-4977-8a86-05b32c2a925b","label":"","guId":"c36fa1ef-5b14-4b16-8f36-f00fd82e90eb","targetRule":"2e60abd8-e73d-440e-b53d-5f1f1a3cf359"},{"target":"54106970-b317-4119-86d8-f10e1e5be15b","source":"7f9fdbb2-2bcf-4d1b-ae1b-503472cc6ba5","label":"","guId":"d4797b1d-5ea8-4f31-a801-2dba5bd6bb6e","targetRule":"2e60abd8-e73d-440e-b53d-5f1f1a3cf359"},{"target":"13a1b7e2-0eee-47ce-b2b6-fc455f8be822","source":"1983119e-7c6c-4fb4-bc43-4a4d4757c01c","label":"Betrixaban","guId":"42041ed5-6526-4344-959d-042eaa32a4da","targetRule":"9fd0a174-3609-44f3-b5f1-410a13b0e865"},{"target":"9a6d0896-5aa2-4bca-848d-d34187120551","source":"1983119e-7c6c-4fb4-bc43-4a4d4757c01c","label":"Rivaroxaban","guId":"42041ed5-6526-4344-959d-042eaa32a4da","targetRule":"79237c44-42d8-47c1-be21-4fb475723d8a"},{"target":"ba0ac0f7-2589-4691-8eab-da54c90c8b64","source":"1983119e-7c6c-4fb4-bc43-4a4d4757c01c","label":"Apixaban","guId":"42041ed5-6526-4344-959d-042eaa32a4da","targetRule":"d3f41473-da90-4ea7-a396-2cc829ab4a9c"},{"target":"13a1b7e2-0eee-47ce-b2b6-fc455f8be822","source":"1983119e-7c6c-4fb4-bc43-4a4d4757c01c","label":"Edoxaban","guId":"42041ed5-6526-4344-959d-042eaa32a4da","targetRule":"9fd0a174-3609-44f3-b5f1-410a13b0e865"},{"target":"54106970-b317-4119-86d8-f10e1e5be15b","source":"13a1b7e2-0eee-47ce-b2b6-fc455f8be822","label":"","guId":"9fd0a174-3609-44f3-b5f1-410a13b0e865","targetRule":"2e60abd8-e73d-440e-b53d-5f1f1a3cf359"},{"target":"54106970-b317-4119-86d8-f10e1e5be15b","source":"9a6d0896-5aa2-4bca-848d-d34187120551","label":"","guId":"79237c44-42d8-47c1-be21-4fb475723d8a","targetRule":"2e60abd8-e73d-440e-b53d-5f1f1a3cf359"},{"target":"54106970-b317-4119-86d8-f10e1e5be15b","source":"ba0ac0f7-2589-4691-8eab-da54c90c8b64","label":"","guId":"d3f41473-da90-4ea7-a396-2cc829ab4a9c","targetRule":"2e60abd8-e73d-440e-b53d-5f1f1a3cf359"},{"target":"6783018b-9eef-4507-9c10-5b5d150d0f57","source":"d359bcfb-7c8f-40a0-9d84-6bb443a478a8","label":"","guId":"bf61481c-fd43-45d4-9eb8-136af1320490","targetRule":"0385aabc-fccb-4a03-b076-deb312f97c0c"},{"target":"f5175785-b752-4647-9fea-9f0d614dd6b4","source":"6783018b-9eef-4507-9c10-5b5d150d0f57","label":"","guId":"0385aabc-fccb-4a03-b076-deb312f97c0c","targetRule":"043fb42f-2f0b-4fe6-89d6-cc691631ed5b"},{"target":"daa13eaf-485e-4b10-b6db-6c86f6691a51","source":"f5175785-b752-4647-9fea-9f0d614dd6b4","label":"3a. Yes","guId":"043fb42f-2f0b-4fe6-89d6-cc691631ed5b","targetRule":"face685c-07b2-478b-a63c-b125bc8923b1"},{"target":"d7dc78cc-4f3c-4042-9488-603ca084747e","source":"f5175785-b752-4647-9fea-9f0d614dd6b4","label":"3b. No","guId":"043fb42f-2f0b-4fe6-89d6-cc691631ed5b","targetRule":"bf150a15-cdb7-4164-827c-221ad6a067f3"},{"target":"54106970-b317-4119-86d8-f10e1e5be15b","source":"daa13eaf-485e-4b10-b6db-6c86f6691a51","label":"","guId":"face685c-07b2-478b-a63c-b125bc8923b1","targetRule":"2e60abd8-e73d-440e-b53d-5f1f1a3cf359"},{"target":"54106970-b317-4119-86d8-f10e1e5be15b","source":"d7dc78cc-4f3c-4042-9488-603ca084747e","label":"","guId":"bf150a15-cdb7-4164-827c-221ad6a067f3","targetRule":"2e60abd8-e73d-440e-b53d-5f1f1a3cf359"},{"target":"56993c2a-46f9-4357-b88e-e08ba0bb2e27","source":"080a7c12-227e-41e5-9248-d49500f9a13f","label":"VKA","guId":"ecac9c52-1c79-4edf-b3f8-2c6b82360f23","targetRule":"b3405430-d853-48bd-b561-23b4e05a642a"},{"target":"56993c2a-46f9-4357-b88e-e08ba0bb2e27","source":"080a7c12-227e-41e5-9248-d49500f9a13f","label":"DOAC","guId":"ecac9c52-1c79-4edf-b3f8-2c6b82360f23","targetRule":"88f790ee-df1b-41b5-bdc7-2ab945142d5e"},{"target":"d359bcfb-7c8f-40a0-9d84-6bb443a478a8","source":"56993c2a-46f9-4357-b88e-e08ba0bb2e27","label":"9a. Yes","guId":"b3405430-d853-48bd-b561-23b4e05a642a","targetRule":"b5331aa9-86be-49b2-b994-d1e3216553d1"},{"target":"4ee3605c-a53c-451c-8aa2-e575ff94c00d","source":"56993c2a-46f9-4357-b88e-e08ba0bb2e27","label":"9b. No","guId":"b3405430-d853-48bd-b561-23b4e05a642a","targetRule":"6e5ee786-e2e5-4e4a-9354-c9a916082dd6"},{"target":"428cf500-cb15-4149-89c4-7fa976352659","source":"d359bcfb-7c8f-40a0-9d84-6bb443a478a8","label":"","guId":"b5331aa9-86be-49b2-b994-d1e3216553d1","targetRule":"b8785a4f-99d7-466d-a656-2aabbe9c6864"},{"target":"d9c3cec3-8529-4e69-81d0-91b10edda8a8","source":"428cf500-cb15-4149-89c4-7fa976352659","label":"","guId":"b8785a4f-99d7-466d-a656-2aabbe9c6864","targetRule":"0a73ae68-3191-4cf5-a0a7-e1e5e2b8faa4"},{"target":"7ccad62c-279b-4af2-8239-a584e5ed01b8","source":"d9c3cec3-8529-4e69-81d0-91b10edda8a8","label":"","guId":"0a73ae68-3191-4cf5-a0a7-e1e5e2b8faa4","targetRule":"29fc6ed5-26e5-4f8f-9a8e-386276c02dec"},{"target":"","source":"7ccad62c-279b-4af2-8239-a584e5ed01b8","label":"","guId":"29fc6ed5-26e5-4f8f-9a8e-386276c02dec","targetRule":"22d4b312-a658-42e4-82c1-c182f90b77fa"},{"target":"eed79a64-199a-41ea-8f9a-56995d065388","source":"4ee3605c-a53c-451c-8aa2-e575ff94c00d","label":"","guId":"6e5ee786-e2e5-4e4a-9354-c9a916082dd6","targetRule":"11ef13c5-18a1-4fdd-9d79-cfc48a23b987"},{"target":"7ccad62c-279b-4af2-8239-a584e5ed01b8","source":"eed79a64-199a-41ea-8f9a-56995d065388","label":"","guId":"11ef13c5-18a1-4fdd-9d79-cfc48a23b987","targetRule":"29fc6ed5-26e5-4f8f-9a8e-386276c02dec"},{"target":"f2ae5926-d91a-412f-925c-84b40f4b34eb","source":"56993c2a-46f9-4357-b88e-e08ba0bb2e27","label":"9a. Yes","guId":"88f790ee-df1b-41b5-bdc7-2ab945142d5e","targetRule":"67f8beec-e591-4fe3-958a-9c99926274fe"},{"target":"4ee3605c-a53c-451c-8aa2-e575ff94c00d","source":"56993c2a-46f9-4357-b88e-e08ba0bb2e27","label":"9b. No","guId":"88f790ee-df1b-41b5-bdc7-2ab945142d5e","targetRule":"21bc61a6-ef6c-4e14-a8de-e8b806ba7430"},{"target":"addd4542-1172-4ccc-8f25-8ca4ae1ad810","source":"f2ae5926-d91a-412f-925c-84b40f4b34eb","label":"","guId":"67f8beec-e591-4fe3-958a-9c99926274fe","targetRule":"890a0cdb-c373-486d-83ea-b47de7ffb8ea"},{"target":"d9c3cec3-8529-4e69-81d0-91b10edda8a8","source":"addd4542-1172-4ccc-8f25-8ca4ae1ad810","label":"","guId":"890a0cdb-c373-486d-83ea-b47de7ffb8ea","targetRule":"1980c0d6-9b17-4197-8885-d3856cb1247d"},{"target":"7ccad62c-279b-4af2-8239-a584e5ed01b8","source":"d9c3cec3-8529-4e69-81d0-91b10edda8a8","label":"","guId":"1980c0d6-9b17-4197-8885-d3856cb1247d","targetRule":"eee3bf24-b213-4fc3-97cd-6c147ef93812"},{"target":"","source":"7ccad62c-279b-4af2-8239-a584e5ed01b8","label":"","guId":"eee3bf24-b213-4fc3-97cd-6c147ef93812","targetRule":"17ff3fed-bacf-4c1d-82c7-7a0473782deb"},{"target":"2666fd57-6fc4-474e-b277-a0d437f0dcc7","source":"4ee3605c-a53c-451c-8aa2-e575ff94c00d","label":"","guId":"21bc61a6-ef6c-4e14-a8de-e8b806ba7430","targetRule":"013e7d70-6d5c-4c7c-a23d-f12d3746bbe1"},{"target":"7ccad62c-279b-4af2-8239-a584e5ed01b8","source":"2666fd57-6fc4-474e-b277-a0d437f0dcc7","label":"","guId":"013e7d70-6d5c-4c7c-a23d-f12d3746bbe1","targetRule":"eee3bf24-b213-4fc3-97cd-6c147ef93812"}];
    var standardQuestionSetJson = [{"StandardQuestion":null,"StandardAnswer":null,"Expression":null,"QALink":[{"questionGuId":"3bcc2a94-6dda-4063-8bd4-f124b9615cf7","ordering":2,"id":665150,"guId":"95eb7cc7-a53a-4e5e-a148-b25b9d094425","expressionType":"Show","expressionGuId":"","deletedByUserGuId":"","dateDeleted":"","answerGuId":"228771bc-b394-462f-81a5-b7e3cb7a2702"},{"questionGuId":"3bcc2a94-6dda-4063-8bd4-f124b9615cf7","ordering":7,"id":663426,"guId":"6a561982-e920-4fa1-ab73-a4f516c7a1a4","expressionType":"Show","expressionGuId":"","deletedByUserGuId":"","dateDeleted":"","answerGuId":"5756cbdf-81b7-4415-8ab1-5d398d3edb12"},{"questionGuId":"3bcc2a94-6dda-4063-8bd4-f124b9615cf7","ordering":6,"id":663427,"guId":"c1066aa9-ba01-44fb-900b-bfef039d046c","expressionType":"Show","expressionGuId":"","deletedByUserGuId":"","dateDeleted":"","answerGuId":"dbf7b314-4c0f-4895-944a-d517e8cdf13b"},{"questionGuId":"3bcc2a94-6dda-4063-8bd4-f124b9615cf7","ordering":1,"id":663428,"guId":"5c276555-7c0e-4ce9-84b2-0350b7d7d3d6","expressionType":"Show","expressionGuId":"","deletedByUserGuId":"","dateDeleted":"","answerGuId":"ab14117a-c4fb-436a-afe4-2b1c91378468"},{"questionGuId":"3bcc2a94-6dda-4063-8bd4-f124b9615cf7","ordering":3,"id":663429,"guId":"1a8a1944-1b67-447a-8f95-b0d894bee004","expressionType":"Show","expressionGuId":"","deletedByUserGuId":"","dateDeleted":"","answerGuId":"7aafc17d-10c4-4db2-ac85-5e9b9cd53b39"},{"questionGuId":"3bcc2a94-6dda-4063-8bd4-f124b9615cf7","ordering":4,"id":663430,"guId":"2acbb60b-de9e-4989-8dcf-86087f3cf2fa","expressionType":"Show","expressionGuId":"","deletedByUserGuId":"","dateDeleted":"","answerGuId":"ab1b2396-5817-4187-a692-6b6f4c3f29ae"},{"questionGuId":"3bcc2a94-6dda-4063-8bd4-f124b9615cf7","ordering":5,"id":663431,"guId":"b92a9722-9a61-47a3-8cf3-20c91f77e9f7","expressionType":"Show","expressionGuId":"","deletedByUserGuId":"","dateDeleted":"","answerGuId":"732c5000-28c2-466b-8ec9-bb7270c9645e"},{"questionGuId":"3bcc2a94-6dda-4063-8bd4-f124b9615cf7","ordering":8,"id":663425,"guId":"f6cef47f-9339-4673-be9b-a341d77eeb94","expressionType":"Show","expressionGuId":"","deletedByUserGuId":"","dateDeleted":"","answerGuId":"9a574412-384c-41b4-98b1-22b77bf7fd3d"}],"updatedByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","tabular":false,"showExecute":true,"sequence":0,"recordStateTimeout":1,"recordStateMeasureUnit":"Years","recordState":0,"measureTypeGuId":0,"linkedLanguageGuIds":"","layQuestion":"","label":"1. Anticoag Selection","keywords":"","internalTableAttribute":"","industryCodeGuIds":"","industryClassification":"","id":663424,"helpText":"","guId":"3bcc2a94-6dda-4063-8bd4-f124b9615cf7","externalIdentifier":"1","extension":"~","expertQuestion":"Drug:","enableAgentComment":false,"defaultValue":"","dateUpdated":1603983092781,"dateUpdatedSpecified":true,"dateDeleted":"","dateCreated":1596040945342,"createdByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","comment":"","canBeModified":true,"canBeModifiedSpecified":true,"baseQuestion":"Which anticoagulant is your patient taking?","assetType":"StandardQuestion","assetSubType":"MultipleChoiceSingleAnswer","active":true,"activeSpecified":true,"expressionField":null,"standardQuestionField":null,"standardAnswerField":null,"ReferenceLink":null},{"StandardQuestion":null,"StandardAnswer":null,"Expression":null,"QALink":[{"questionGuId":"1bd28e57-e5a0-4217-8feb-04bbce28327e","ordering":4,"id":663441,"guId":"a3571e8a-a167-4d9d-95de-7412e3eb8343","expressionType":"Show","expressionGuId":"","deletedByUserGuId":"","dateDeleted":"","answerGuId":"9a574412-384c-41b4-98b1-22b77bf7fd3d"},{"questionGuId":"1bd28e57-e5a0-4217-8feb-04bbce28327e","ordering":3,"id":663442,"guId":"a2fb74a5-a6fa-4ec8-a763-daa3a4b2b4f3","expressionType":"Show","expressionGuId":"","deletedByUserGuId":"","dateDeleted":"","answerGuId":"5756cbdf-81b7-4415-8ab1-5d398d3edb12"},{"questionGuId":"1bd28e57-e5a0-4217-8feb-04bbce28327e","ordering":1,"id":663443,"guId":"e6b8515c-1b75-491f-91f2-817f558267f0","expressionType":"Show","expressionGuId":"","deletedByUserGuId":"","dateDeleted":"","answerGuId":"a7928a95-fb2d-4f57-98f7-4d633870495b"},{"questionGuId":"1bd28e57-e5a0-4217-8feb-04bbce28327e","ordering":2,"id":663444,"guId":"0a96dd67-99ac-4b07-a753-15556bb2562f","expressionType":"Show","expressionGuId":"","deletedByUserGuId":"","dateDeleted":"","answerGuId":"99d43797-8b8a-42b0-9d3f-68ba6a3eb700"}],"updatedByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","tabular":false,"showExecute":true,"sequence":0,"recordStateTimeout":1,"recordStateMeasureUnit":"Years","recordState":0,"measureTypeGuId":0,"linkedLanguageGuIds":"","layQuestion":"","label":"2. Bleed Severity","keywords":"","internalTableAttribute":"","industryCodeGuIds":"","industryClassification":"","id":663439,"helpText":"Major bleed(s) are associated with one or more of the following factors:  \n• Hemodynamic instability \n• Occurring at a critical site (see Quick Reference for full list of Critical Site Bleeds) \n• Decrease of hemoglobin ≥ 2 g/dL (when baseline is known) or requiring transfusion of ≥ 2 units of packed RBCs.\n- Nonmajor bleeds are clinically relevant but do not meet the criteria for a major bleed.","guId":"1bd28e57-e5a0-4217-8feb-04bbce28327e","externalIdentifier":"2","extension":"~","expertQuestion":"Bleed severity:","enableAgentComment":false,"defaultValue":"","dateUpdated":1603983355745,"dateUpdatedSpecified":true,"dateDeleted":"","dateCreated":1596040945461,"createdByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","comment":"","canBeModified":true,"canBeModifiedSpecified":true,"baseQuestion":"<P>What is the bleed severity?</P>","assetType":"StandardQuestion","assetSubType":"MultipleChoiceSingleAnswer","active":true,"activeSpecified":true,"expressionField":null,"standardQuestionField":null,"standardAnswerField":null,"ReferenceLink":null},{"StandardQuestion":null,"StandardAnswer":null,"Expression":null,"QALink":[{"questionGuId":"f5175785-b752-4647-9fea-9f0d614dd6b4","ordering":1,"id":663477,"guId":"62cc8d76-09d7-40f0-aae3-8aadb974ae2a","expressionType":"Show","expressionGuId":"","deletedByUserGuId":"","dateDeleted":"","answerGuId":"bb097aaf-38ed-4f00-97ed-953eb2b037f1"},{"questionGuId":"f5175785-b752-4647-9fea-9f0d614dd6b4","ordering":2,"id":663478,"guId":"73ede5d1-7857-4e7f-a094-d02c2f5b1363","expressionType":"Show","expressionGuId":"","deletedByUserGuId":"","dateDeleted":"","answerGuId":"437f1203-86b3-4aef-972a-133291e3c8f6"},{"questionGuId":"f5175785-b752-4647-9fea-9f0d614dd6b4","ordering":4,"id":663479,"guId":"b17246bc-1643-4740-8a3b-c7ad7538fba5","expressionType":"Show","expressionGuId":"","deletedByUserGuId":"","dateDeleted":"","answerGuId":"9a574412-384c-41b4-98b1-22b77bf7fd3d"},{"questionGuId":"f5175785-b752-4647-9fea-9f0d614dd6b4","ordering":3,"id":663480,"guId":"60f2ac4b-c712-4cb2-976c-d2d375f4101d","expressionType":"Show","expressionGuId":"","deletedByUserGuId":"","dateDeleted":"","answerGuId":"5756cbdf-81b7-4415-8ab1-5d398d3edb12"}],"updatedByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","tabular":false,"showExecute":true,"sequence":0,"recordStateTimeout":1,"recordStateMeasureUnit":"Years","recordState":0,"measureTypeGuId":0,"linkedLanguageGuIds":"","layQuestion":"","label":"3. Is Bleed Lifethreatening?","keywords":"Bleed","internalTableAttribute":"","industryCodeGuIds":"","industryClassification":"","id":663474,"helpText":"Critical site bleeds compromise an organ's function. See Critical Site Bleed table in the Quick Reference section.","guId":"f5175785-b752-4647-9fea-9f0d614dd6b4","externalIdentifier":"3","extension":"~","expertQuestion":"<P>Life-threatening or critical site bleed?</P>","enableAgentComment":false,"defaultValue":"","dateUpdated":1603983322411,"dateUpdatedSpecified":true,"dateDeleted":"","dateCreated":1596040945758,"createdByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","comment":"","canBeModified":true,"canBeModifiedSpecified":true,"baseQuestion":"<P>Is the bleed life-threatening or at a critical site?</P>","assetType":"StandardQuestion","assetSubType":"MultipleChoiceSingleAnswer","active":true,"activeSpecified":true,"expressionField":null,"standardQuestionField":null,"standardAnswerField":null,"ReferenceLink":null},{"StandardQuestion":null,"StandardAnswer":null,"Expression":null,"QALink":[{"questionGuId":"56993c2a-46f9-4357-b88e-e08ba0bb2e27","ordering":4,"id":663622,"guId":"6f4cc2a9-6781-49ba-9082-09719c271733","expressionType":"Show","expressionGuId":"","deletedByUserGuId":"","dateDeleted":"","answerGuId":"9a574412-384c-41b4-98b1-22b77bf7fd3d"},{"questionGuId":"56993c2a-46f9-4357-b88e-e08ba0bb2e27","ordering":3,"id":663623,"guId":"b77275a5-f4a2-4ec9-ad0d-8ced4412b59f","expressionType":"Show","expressionGuId":"","deletedByUserGuId":"","dateDeleted":"","answerGuId":"5756cbdf-81b7-4415-8ab1-5d398d3edb12"},{"questionGuId":"56993c2a-46f9-4357-b88e-e08ba0bb2e27","ordering":1,"id":663624,"guId":"af1e09db-a666-4e13-9558-dc49b4b20a96","expressionType":"Show","expressionGuId":"","deletedByUserGuId":"","dateDeleted":"","answerGuId":"ed9e44c6-bf4c-423a-9de6-d596cf9b6e07"},{"questionGuId":"56993c2a-46f9-4357-b88e-e08ba0bb2e27","ordering":2,"id":663625,"guId":"c7449be6-60bf-49b4-9432-a0062fe3a1b3","expressionType":"Show","expressionGuId":"","deletedByUserGuId":"","dateDeleted":"","answerGuId":"60b5cf96-0620-45eb-abc4-a6384ce10c79"}],"updatedByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","tabular":false,"showExecute":true,"sequence":0,"recordStateTimeout":1,"recordStateMeasureUnit":"Years","recordState":0,"measureTypeGuId":0,"linkedLanguageGuIds":"","layQuestion":"","label":"9. Does Bleed Require Hospitalization?","keywords":"Bleed","internalTableAttribute":"","industryCodeGuIds":"","industryClassification":"","id":663621,"helpText":"","guId":"56993c2a-46f9-4357-b88e-e08ba0bb2e27","externalIdentifier":"9","extension":"~","expertQuestion":"Does the bleed require hospitalization, surgical/procedural intervention, or transfusion?","enableAgentComment":false,"defaultValue":"","dateUpdated":1603983287433,"dateUpdatedSpecified":true,"dateDeleted":"","dateCreated":1596040946862,"createdByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","comment":"","canBeModified":true,"canBeModifiedSpecified":true,"baseQuestion":"Does the bleed require hospitalization, surgical/procedural intervention, or transfusion?","assetType":"StandardQuestion","assetSubType":"MultipleChoiceSingleAnswer","active":true,"activeSpecified":true,"expressionField":null,"standardQuestionField":null,"standardAnswerField":null,"ReferenceLink":null}];

    var assetNode = [{"active":true,"activeSpecified":true,"assetSubType":"Default","assetType":"Algorithm","authorComment":"","authorState":1,"baseDescription":"<P>Figure 2: Assessing Bleed Severity and Managing Major and Non-Major Bleeds</P>","canBeModified":true,"canBeModifiedSpecified":true,"comment":"","createdByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","dateCreated":1596040945219,"dateDeleted":"","dateLastReviewed":"","dateUpdated":1516296954100,"dateUpdatedSpecified":true,"expertDescription":"","extension":"~","guId":"a4973daf-fc93-41d0-b7fd-cd6faaecc9bb","helpText":"","id":663412,"industryCodeGuIds":"","keywords":"","label":"1. Manage a Bleed","layDescription":"","recordState":0,"recordStateMeasureUnit":"","recordStateTimeout":0,"reviewedByUserGuId":"","sequence":663161,"summaryTitle":"","tabular":false,"updatedByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d"},{"weightValue":"N/A","label":"1f. Betrixaban","updatedByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","tabular":false,"expertQuestion":null,"showImageLabel":true,"sequence":0,"mediaGuId":"","layAnswer":"","keywords":"","id":665147,"helpText":"","guId":"228771bc-b394-462f-81a5-b7e3cb7a2702","externalIdentifier":"1f","extension":"~","expertAnswer":"Betrixaban","dateUpdated":1603983043072,"dateUpdatedSpecified":true,"dateDeleted":"","dateCreated":1601418089739,"createdByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","comment":"","canBeModified":true,"canBeModifiedSpecified":true,"baseAnswer":"Betrixaban","assetType":"StandardAnswer","assetSubType":"MultipleChoice","active":true,"activeSpecified":true,"exclusive":false,"Expression":null,"referenceLinkField":null},{"weightValue":"N/A","label":"Any","updatedByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","tabular":false,"expertQuestion":null,"showImageLabel":false,"sequence":0,"mediaGuId":"","layAnswer":"Any","keywords":"","id":663418,"helpText":"Any answer is selected.","guId":"5756cbdf-81b7-4415-8ab1-5d398d3edb12","externalIdentifier":"","extension":"~","expertAnswer":"Any","dateUpdated":1276528460000,"dateUpdatedSpecified":true,"dateDeleted":"","dateCreated":1596040945287,"createdByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","comment":"","canBeModified":false,"canBeModifiedSpecified":true,"baseAnswer":"Any","assetType":"StandardAnswer","assetSubType":"General","active":true,"activeSpecified":true,"exclusive":false,"Expression":null,"referenceLinkField":null},{"weightValue":"N/A","label":"1e. VKA","updatedByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","tabular":false,"expertQuestion":null,"showImageLabel":true,"sequence":0,"mediaGuId":"","layAnswer":"","keywords":"","id":663419,"helpText":"Vitamin K Antagonist e.g. warfarin and other coumarins","guId":"dbf7b314-4c0f-4895-944a-d517e8cdf13b","externalIdentifier":"1e","extension":"~","expertAnswer":"VKA","dateUpdated":1603996299189,"dateUpdatedSpecified":true,"dateDeleted":"","dateCreated":1596040945297,"createdByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","comment":"","canBeModified":true,"canBeModifiedSpecified":true,"baseAnswer":"VKA","assetType":"StandardAnswer","assetSubType":"MultipleChoice","active":true,"activeSpecified":true,"exclusive":false,"Expression":null,"referenceLinkField":null},{"weightValue":"N/A","label":"1a. Apixaban","updatedByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","tabular":false,"expertQuestion":null,"showImageLabel":true,"sequence":0,"mediaGuId":"","layAnswer":"","keywords":"","id":663420,"helpText":"","guId":"ab14117a-c4fb-436a-afe4-2b1c91378468","externalIdentifier":"1a","extension":"~","expertAnswer":"Apixaban","dateUpdated":1603983030819,"dateUpdatedSpecified":true,"dateDeleted":"","dateCreated":1596040945306,"createdByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","comment":"","canBeModified":true,"canBeModifiedSpecified":true,"baseAnswer":"Apixaban","assetType":"StandardAnswer","assetSubType":"MultipleChoice","active":true,"activeSpecified":true,"exclusive":false,"Expression":null,"referenceLinkField":null},{"weightValue":"N/A","label":"1b. Dabigatran","updatedByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","tabular":false,"expertQuestion":null,"showImageLabel":true,"sequence":0,"mediaGuId":"","layAnswer":"","keywords":"","id":663421,"helpText":"","guId":"7aafc17d-10c4-4db2-ac85-5e9b9cd53b39","externalIdentifier":"1b","extension":"~","expertAnswer":"Dabigatran","dateUpdated":1603983053666,"dateUpdatedSpecified":true,"dateDeleted":"","dateCreated":1596040945314,"createdByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","comment":"","canBeModified":true,"canBeModifiedSpecified":true,"baseAnswer":"Dabigatran","assetType":"StandardAnswer","assetSubType":"MultipleChoice","active":true,"activeSpecified":true,"exclusive":false,"Expression":null,"referenceLinkField":null},{"weightValue":"N/A","label":"1c. Edoxaban","updatedByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","tabular":false,"expertQuestion":null,"showImageLabel":true,"sequence":0,"mediaGuId":"","layAnswer":"","keywords":"","id":663422,"helpText":"","guId":"ab1b2396-5817-4187-a692-6b6f4c3f29ae","externalIdentifier":"1c","extension":"~","expertAnswer":"Edoxaban","dateUpdated":1603983066244,"dateUpdatedSpecified":true,"dateDeleted":"","dateCreated":1596040945323,"createdByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","comment":"","canBeModified":true,"canBeModifiedSpecified":true,"baseAnswer":"Edoxaban","assetType":"StandardAnswer","assetSubType":"MultipleChoice","active":true,"activeSpecified":true,"exclusive":false,"Expression":null,"referenceLinkField":null},{"weightValue":"N/A","label":"1d. Rivaroxaban","updatedByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","tabular":false,"expertQuestion":null,"showImageLabel":true,"sequence":0,"mediaGuId":"","layAnswer":"","keywords":"","id":663423,"helpText":"","guId":"732c5000-28c2-466b-8ec9-bb7270c9645e","externalIdentifier":"1d","extension":"~","expertAnswer":"Rivaroxaban","dateUpdated":1603983078078,"dateUpdatedSpecified":true,"dateDeleted":"","dateCreated":1596040945332,"createdByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","comment":"","canBeModified":true,"canBeModifiedSpecified":true,"baseAnswer":"Rivaroxaban","assetType":"StandardAnswer","assetSubType":"MultipleChoice","active":true,"activeSpecified":true,"exclusive":false,"Expression":null,"referenceLinkField":null},{"weightValue":"N/A","label":"No Answer","updatedByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","tabular":false,"expertQuestion":null,"showImageLabel":false,"sequence":0,"mediaGuId":"","layAnswer":"No Answer","keywords":"","id":663417,"helpText":"No answer is selected.","guId":"9a574412-384c-41b4-98b1-22b77bf7fd3d","externalIdentifier":"","extension":"~","expertAnswer":"No Answer","dateUpdated":1276528460000,"dateUpdatedSpecified":true,"dateDeleted":"","dateCreated":1596040945278,"createdByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","comment":"","canBeModified":false,"canBeModifiedSpecified":true,"baseAnswer":"No Answer","assetType":"StandardAnswer","assetSubType":"General","active":true,"activeSpecified":true,"exclusive":false,"Expression":null,"referenceLinkField":null},{"StandardQuestion":null,"StandardAnswer":null,"Expression":null,"QALink":[{"questionGuId":"3bcc2a94-6dda-4063-8bd4-f124b9615cf7","ordering":2,"id":665150,"guId":"95eb7cc7-a53a-4e5e-a148-b25b9d094425","expressionType":"Show","expressionGuId":"","deletedByUserGuId":"","dateDeleted":"","answerGuId":"228771bc-b394-462f-81a5-b7e3cb7a2702"},{"questionGuId":"3bcc2a94-6dda-4063-8bd4-f124b9615cf7","ordering":7,"id":663426,"guId":"6a561982-e920-4fa1-ab73-a4f516c7a1a4","expressionType":"Show","expressionGuId":"","deletedByUserGuId":"","dateDeleted":"","answerGuId":"5756cbdf-81b7-4415-8ab1-5d398d3edb12"},{"questionGuId":"3bcc2a94-6dda-4063-8bd4-f124b9615cf7","ordering":6,"id":663427,"guId":"c1066aa9-ba01-44fb-900b-bfef039d046c","expressionType":"Show","expressionGuId":"","deletedByUserGuId":"","dateDeleted":"","answerGuId":"dbf7b314-4c0f-4895-944a-d517e8cdf13b"},{"questionGuId":"3bcc2a94-6dda-4063-8bd4-f124b9615cf7","ordering":1,"id":663428,"guId":"5c276555-7c0e-4ce9-84b2-0350b7d7d3d6","expressionType":"Show","expressionGuId":"","deletedByUserGuId":"","dateDeleted":"","answerGuId":"ab14117a-c4fb-436a-afe4-2b1c91378468"},{"questionGuId":"3bcc2a94-6dda-4063-8bd4-f124b9615cf7","ordering":3,"id":663429,"guId":"1a8a1944-1b67-447a-8f95-b0d894bee004","expressionType":"Show","expressionGuId":"","deletedByUserGuId":"","dateDeleted":"","answerGuId":"7aafc17d-10c4-4db2-ac85-5e9b9cd53b39"},{"questionGuId":"3bcc2a94-6dda-4063-8bd4-f124b9615cf7","ordering":4,"id":663430,"guId":"2acbb60b-de9e-4989-8dcf-86087f3cf2fa","expressionType":"Show","expressionGuId":"","deletedByUserGuId":"","dateDeleted":"","answerGuId":"ab1b2396-5817-4187-a692-6b6f4c3f29ae"},{"questionGuId":"3bcc2a94-6dda-4063-8bd4-f124b9615cf7","ordering":5,"id":663431,"guId":"b92a9722-9a61-47a3-8cf3-20c91f77e9f7","expressionType":"Show","expressionGuId":"","deletedByUserGuId":"","dateDeleted":"","answerGuId":"732c5000-28c2-466b-8ec9-bb7270c9645e"},{"questionGuId":"3bcc2a94-6dda-4063-8bd4-f124b9615cf7","ordering":8,"id":663425,"guId":"f6cef47f-9339-4673-be9b-a341d77eeb94","expressionType":"Show","expressionGuId":"","deletedByUserGuId":"","dateDeleted":"","answerGuId":"9a574412-384c-41b4-98b1-22b77bf7fd3d"}],"updatedByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","tabular":false,"showExecute":true,"sequence":0,"recordStateTimeout":1,"recordStateMeasureUnit":"Years","recordState":0,"measureTypeGuId":0,"linkedLanguageGuIds":"","layQuestion":"","label":"1. Anticoag Selection","keywords":"","internalTableAttribute":"","industryCodeGuIds":"","industryClassification":"","id":663424,"helpText":"","guId":"3bcc2a94-6dda-4063-8bd4-f124b9615cf7","externalIdentifier":"1","extension":"~","expertQuestion":"Drug:","enableAgentComment":false,"defaultValue":"","dateUpdated":1603983092781,"dateUpdatedSpecified":true,"dateDeleted":"","dateCreated":1596040945342,"createdByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","comment":"","canBeModified":true,"canBeModifiedSpecified":true,"baseQuestion":"Which anticoagulant is your patient taking?","assetType":"StandardQuestion","assetSubType":"MultipleChoiceSingleAnswer","active":true,"activeSpecified":true,"expressionField":null,"standardQuestionField":null,"standardAnswerField":null,"ReferenceLink":null},{"weightValue":"N/A","label":"2a. Major","updatedByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","tabular":false,"expertQuestion":null,"showImageLabel":true,"sequence":0,"mediaGuId":"","layAnswer":"","keywords":"","id":663434,"helpText":"","guId":"a7928a95-fb2d-4f57-98f7-4d633870495b","externalIdentifier":"2a","extension":"~","expertAnswer":"Major","dateUpdated":1603983341257,"dateUpdatedSpecified":true,"dateDeleted":"","dateCreated":1596040945415,"createdByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","comment":"","canBeModified":true,"canBeModifiedSpecified":true,"baseAnswer":"<P>Major</P>","assetType":"StandardAnswer","assetSubType":"MultipleChoice","active":true,"activeSpecified":true,"exclusive":false,"Expression":null,"referenceLinkField":null},{"weightValue":"N/A","label":"2b. Non-Major","updatedByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","tabular":false,"expertQuestion":null,"showImageLabel":true,"sequence":0,"mediaGuId":"","layAnswer":"","keywords":"","id":663436,"helpText":"","guId":"99d43797-8b8a-42b0-9d3f-68ba6a3eb700","externalIdentifier":"2b","extension":"~","expertAnswer":"<P>Non-major</P>","dateUpdated":1603983352459,"dateUpdatedSpecified":true,"dateDeleted":"","dateCreated":1596040945439,"createdByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","comment":"","canBeModified":true,"canBeModifiedSpecified":true,"baseAnswer":"Nonmajor","assetType":"StandardAnswer","assetSubType":"MultipleChoice","active":true,"activeSpecified":true,"exclusive":false,"Expression":null,"referenceLinkField":null},{"StandardQuestion":null,"StandardAnswer":null,"Expression":null,"QALink":[{"questionGuId":"1bd28e57-e5a0-4217-8feb-04bbce28327e","ordering":4,"id":663441,"guId":"a3571e8a-a167-4d9d-95de-7412e3eb8343","expressionType":"Show","expressionGuId":"","deletedByUserGuId":"","dateDeleted":"","answerGuId":"9a574412-384c-41b4-98b1-22b77bf7fd3d"},{"questionGuId":"1bd28e57-e5a0-4217-8feb-04bbce28327e","ordering":3,"id":663442,"guId":"a2fb74a5-a6fa-4ec8-a763-daa3a4b2b4f3","expressionType":"Show","expressionGuId":"","deletedByUserGuId":"","dateDeleted":"","answerGuId":"5756cbdf-81b7-4415-8ab1-5d398d3edb12"},{"questionGuId":"1bd28e57-e5a0-4217-8feb-04bbce28327e","ordering":1,"id":663443,"guId":"e6b8515c-1b75-491f-91f2-817f558267f0","expressionType":"Show","expressionGuId":"","deletedByUserGuId":"","dateDeleted":"","answerGuId":"a7928a95-fb2d-4f57-98f7-4d633870495b"},{"questionGuId":"1bd28e57-e5a0-4217-8feb-04bbce28327e","ordering":2,"id":663444,"guId":"0a96dd67-99ac-4b07-a753-15556bb2562f","expressionType":"Show","expressionGuId":"","deletedByUserGuId":"","dateDeleted":"","answerGuId":"99d43797-8b8a-42b0-9d3f-68ba6a3eb700"}],"updatedByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","tabular":false,"showExecute":true,"sequence":0,"recordStateTimeout":1,"recordStateMeasureUnit":"Years","recordState":0,"measureTypeGuId":0,"linkedLanguageGuIds":"","layQuestion":"","label":"2. Bleed Severity","keywords":"","internalTableAttribute":"","industryCodeGuIds":"","industryClassification":"","id":663439,"helpText":"Major bleed(s) are associated with one or more of the following factors:  \n• Hemodynamic instability \n• Occurring at a critical site (see Quick Reference for full list of Critical Site Bleeds) \n• Decrease of hemoglobin ≥ 2 g/dL (when baseline is known) or requiring transfusion of ≥ 2 units of packed RBCs.\n- Nonmajor bleeds are clinically relevant but do not meet the criteria for a major bleed.","guId":"1bd28e57-e5a0-4217-8feb-04bbce28327e","externalIdentifier":"2","extension":"~","expertQuestion":"Bleed severity:","enableAgentComment":false,"defaultValue":"","dateUpdated":1603983355745,"dateUpdatedSpecified":true,"dateDeleted":"","dateCreated":1596040945461,"createdByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","comment":"","canBeModified":true,"canBeModifiedSpecified":true,"baseQuestion":"<P>What is the bleed severity?</P>","assetType":"StandardQuestion","assetSubType":"MultipleChoiceSingleAnswer","active":true,"activeSpecified":true,"expressionField":null,"standardQuestionField":null,"standardAnswerField":null,"ReferenceLink":null},{"Items":[{"questionGuId":"f8e8f960-6d9d-4808-8a4a-b3c6ef8deaf6","ordering":1,"id":663452,"guId":"93719dd7-4491-4238-ac75-9ecc428b2de8","expressionType":"","expressionGuId":"","deletedByUserGuId":"","dateDeleted":"","answerGuId":"ceeb26d0-a431-4009-bf4c-4b81c751cb53"},{"questionGuId":"f8e8f960-6d9d-4808-8a4a-b3c6ef8deaf6","ordering":1,"id":663453,"guId":"8c6fe926-2b1b-4506-b884-78b4435f6393","expressionType":"","expressionGuId":"","deletedByUserGuId":"","dateDeleted":"","answerGuId":"d8e5a369-89ae-41cf-9299-72b27c57dd13"},{"questionGuId":"f8e8f960-6d9d-4808-8a4a-b3c6ef8deaf6","ordering":1,"id":663454,"guId":"78ebc292-e066-45ad-963e-0e64154897e5","expressionType":"","expressionGuId":"","deletedByUserGuId":"","dateDeleted":"","answerGuId":"a54548ca-470a-44f4-b1d3-e675c2e8028e"},{"questionGuId":"f8e8f960-6d9d-4808-8a4a-b3c6ef8deaf6","ordering":1,"id":663455,"guId":"a348243e-ce31-43b0-83d7-6b0e37e613f5","expressionType":"","expressionGuId":"","deletedByUserGuId":"","dateDeleted":"","answerGuId":"6d3d939f-6682-4cdf-9843-fa6585411576"},{"variableType":0,"id":663456,"ordering":1,"guId":"a67bd668-caed-4958-904e-5275af098e8d","expressionGuId":"f8e8f960-6d9d-4808-8a4a-b3c6ef8deaf6","deletedByUserGuId":"","dateDeleted":"","assetHeaderGuId":"1bd28e57-e5a0-4217-8feb-04bbce28327e"}],"updatedByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","traverseIfTrueType":"None","traverseIfTrueGuId":"","tabular":false,"showExecute":true,"sequence":0,"recordStateTimeout":"1","recordStateMeasureUnit":"","recordState":0,"linkedLanguageGuIds":"","layQuestion":"Major Bleed","label":"Major Bleed","keywords":"","industryCodeGuIds":"","industryClassification":"","id":663451,"helpText":"","guId":"f8e8f960-6d9d-4808-8a4a-b3c6ef8deaf6","extension":"~","expression":" isSelected([{2. Bleed Severity}],\"2a. Major\")","expertQuestion":"Major Bleed","enableAgentComment":false,"dateUpdated":1516296516244,"dateUpdatedSpecified":true,"dateDeleted":"","dateCreated":1596040945549,"createdByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","comment":"","canBeModified":true,"canBeModifiedSpecified":true,"baseQuestion":"Major Bleed","assetType":"Expression","assetSubType":"Default","active":true,"activeSpecified":true},{"ValueCheckAnswerLink":null,"updatedByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","tabular":false,"sequence":0,"layAnswer":"No Answer","label":"No Answer","keywords":"","id":663459,"helpText":"No answer is selected.","guId":"66c3572d-88c6-4813-a059-aa2ed8c37699","extension":"~","expression":"No Answer","expertAnswer":"No Answer","dateUpdated":1467383160733,"dateUpdatedSpecified":true,"dateDeleted":"","dateCreated":1596040945624,"createdByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","comment":"","canBeModified":false,"canBeModifiedSpecified":true,"baseAnswer":"No Answer","assetType":"ValueCheckAnswer","assetSubType":"Default","active":true,"activeSpecified":true},{"ValueCheckAnswerLink":null,"updatedByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","tabular":false,"sequence":0,"layAnswer":"Any","label":"Any","keywords":"","id":663460,"helpText":"Any answer is selected.","guId":"5388f40f-a046-489a-9c8b-6af2bb5f9b34","extension":"~","expression":"Any","expertAnswer":"Any","dateUpdated":1467383160743,"dateUpdatedSpecified":true,"dateDeleted":"","dateCreated":1596040945633,"createdByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","comment":"","canBeModified":false,"canBeModifiedSpecified":true,"baseAnswer":"Any","assetType":"ValueCheckAnswer","assetSubType":"Default","active":true,"activeSpecified":true},{"ValueCheckAnswerLink":{"variableType":"","valueCheckAnswerGuId":"0820ef5d-415a-4d4e-91fb-14622a304684","ordering":1,"id":663462,"guId":"a92531db-b20e-4aaa-8bd6-3992d001bec3","deletedByUserGuId":"","dateDeleted":"","assetHeaderGuId":"3bcc2a94-6dda-4063-8bd4-f124b9615cf7"},"updatedByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","tabular":false,"sequence":0,"layAnswer":"","label":"VKA","keywords":"","id":663461,"helpText":"","guId":"0820ef5d-415a-4d4e-91fb-14622a304684","extension":"~","expression":" isSelected([{1. Anticoag Selection}],\"1e. VKA\")","expertAnswer":"","dateUpdated":1511806708960,"dateUpdatedSpecified":true,"dateDeleted":"","dateCreated":1596040945641,"createdByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","comment":"","canBeModified":true,"canBeModifiedSpecified":true,"baseAnswer":"VKA","assetType":"ValueCheckAnswer","assetSubType":"Default","active":true,"activeSpecified":true},{"ValueCheckAnswerLink":{"variableType":"","valueCheckAnswerGuId":"83cdd0f0-a7b5-4147-ab84-770d75692749","ordering":1,"id":663464,"guId":"b3902ffa-11c3-4854-afc7-c7249ddb9f81","deletedByUserGuId":"","dateDeleted":"","assetHeaderGuId":"3bcc2a94-6dda-4063-8bd4-f124b9615cf7"},"updatedByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","tabular":false,"sequence":0,"layAnswer":"","label":"DOAC","keywords":"Bleed","id":663463,"helpText":"","guId":"83cdd0f0-a7b5-4147-ab84-770d75692749","extension":"~","expression":" isAnySelected([{1. Anticoag Selection}],\"1d. Rivaroxaban\",\"1f. Betrixaban\",\"1c. Edoxaban\",\"1a. Apixaban\",\"1b. Dabigatran\")","expertAnswer":"","dateUpdated":1601933610062,"dateUpdatedSpecified":true,"dateDeleted":"","dateCreated":1596040945662,"createdByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","comment":"","canBeModified":true,"canBeModifiedSpecified":true,"baseAnswer":"DOAC","assetType":"ValueCheckAnswer","assetSubType":"Default","active":true,"activeSpecified":true},{"QALink":[{"questionGuId":"080a7c12-227e-41e5-9248-d49500f9a13f","ordering":1,"id":663466,"guId":"f1c19ed9-b51b-4ca6-89b8-f6267e5cbb55","expressionType":"","expressionGuId":"","deletedByUserGuId":"","dateDeleted":"","answerGuId":"66c3572d-88c6-4813-a059-aa2ed8c37699"},{"questionGuId":"080a7c12-227e-41e5-9248-d49500f9a13f","ordering":2,"id":663467,"guId":"da2463a0-ac11-46c8-88a8-20b11ce52823","expressionType":"","expressionGuId":"","deletedByUserGuId":"","dateDeleted":"","answerGuId":"5388f40f-a046-489a-9c8b-6af2bb5f9b34"},{"questionGuId":"080a7c12-227e-41e5-9248-d49500f9a13f","ordering":3,"id":663468,"guId":"25cd0aea-c3a6-4d4e-8a93-80ad1e3fe1ed","expressionType":"","expressionGuId":"","deletedByUserGuId":"","dateDeleted":"","answerGuId":"0820ef5d-415a-4d4e-91fb-14622a304684"},{"questionGuId":"080a7c12-227e-41e5-9248-d49500f9a13f","ordering":4,"id":663469,"guId":"aa12768a-f7dc-4594-a338-880fee0421e9","expressionType":"","expressionGuId":"","deletedByUserGuId":"","dateDeleted":"","answerGuId":"83cdd0f0-a7b5-4147-ab84-770d75692749"}],"updatedByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","tabular":false,"showExecute":true,"sequence":0,"recordStateTimeout":"1","recordStateMeasureUnit":"Years","recordState":0,"measureUnitGuId":0,"measureTypeGuId":0,"linkedLanguageGuIds":"","layQuestion":"","label":"Anticoagulant","keywords":"Bleed","internalTableAttribute":"","industryCodeGuIds":"","industryClassification":"","id":663465,"helpText":"","guId":"080a7c12-227e-41e5-9248-d49500f9a13f","extension":"~","expertQuestion":"","enableAgentComment":false,"dateUpdated":1601933796699,"dateUpdatedSpecified":true,"dateDeleted":"","dateCreated":1596040945679,"createdByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","comment":"","canBeModified":true,"canBeModifiedSpecified":true,"baseQuestion":"Anticoagulant","assetType":"ValueCheckQuestion","assetSubType":"Default","active":true,"activeSpecified":true},{"weightValue":"N/A","label":"3a. Yes","updatedByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","tabular":false,"expertQuestion":null,"showImageLabel":true,"sequence":0,"mediaGuId":"","layAnswer":"","keywords":"","id":663472,"helpText":"","guId":"bb097aaf-38ed-4f00-97ed-953eb2b037f1","externalIdentifier":"3a","extension":"~","expertAnswer":"Yes","dateUpdated":1603983311358,"dateUpdatedSpecified":true,"dateDeleted":"","dateCreated":1596040945724,"createdByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","comment":"","canBeModified":true,"canBeModifiedSpecified":true,"baseAnswer":"Yes","assetType":"StandardAnswer","assetSubType":"MultipleChoice","active":true,"activeSpecified":true,"exclusive":false,"Expression":null,"referenceLinkField":null},{"weightValue":"N/A","label":"3b. No","updatedByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","tabular":false,"expertQuestion":null,"showImageLabel":true,"sequence":0,"mediaGuId":"","layAnswer":"","keywords":"","id":663473,"helpText":"","guId":"437f1203-86b3-4aef-972a-133291e3c8f6","externalIdentifier":"3b","extension":"~","expertAnswer":"No","dateUpdated":1603983321267,"dateUpdatedSpecified":true,"dateDeleted":"","dateCreated":1596040945736,"createdByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","comment":"","canBeModified":true,"canBeModifiedSpecified":true,"baseAnswer":"No","assetType":"StandardAnswer","assetSubType":"MultipleChoice","active":true,"activeSpecified":true,"exclusive":false,"Expression":null,"referenceLinkField":null},{"StandardQuestion":null,"StandardAnswer":null,"Expression":null,"QALink":[{"questionGuId":"f5175785-b752-4647-9fea-9f0d614dd6b4","ordering":1,"id":663477,"guId":"62cc8d76-09d7-40f0-aae3-8aadb974ae2a","expressionType":"Show","expressionGuId":"","deletedByUserGuId":"","dateDeleted":"","answerGuId":"bb097aaf-38ed-4f00-97ed-953eb2b037f1"},{"questionGuId":"f5175785-b752-4647-9fea-9f0d614dd6b4","ordering":2,"id":663478,"guId":"73ede5d1-7857-4e7f-a094-d02c2f5b1363","expressionType":"Show","expressionGuId":"","deletedByUserGuId":"","dateDeleted":"","answerGuId":"437f1203-86b3-4aef-972a-133291e3c8f6"},{"questionGuId":"f5175785-b752-4647-9fea-9f0d614dd6b4","ordering":4,"id":663479,"guId":"b17246bc-1643-4740-8a3b-c7ad7538fba5","expressionType":"Show","expressionGuId":"","deletedByUserGuId":"","dateDeleted":"","answerGuId":"9a574412-384c-41b4-98b1-22b77bf7fd3d"},{"questionGuId":"f5175785-b752-4647-9fea-9f0d614dd6b4","ordering":3,"id":663480,"guId":"60f2ac4b-c712-4cb2-976c-d2d375f4101d","expressionType":"Show","expressionGuId":"","deletedByUserGuId":"","dateDeleted":"","answerGuId":"5756cbdf-81b7-4415-8ab1-5d398d3edb12"}],"updatedByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","tabular":false,"showExecute":true,"sequence":0,"recordStateTimeout":1,"recordStateMeasureUnit":"Years","recordState":0,"measureTypeGuId":0,"linkedLanguageGuIds":"","layQuestion":"","label":"3. Is Bleed Lifethreatening?","keywords":"Bleed","internalTableAttribute":"","industryCodeGuIds":"","industryClassification":"","id":663474,"helpText":"Critical site bleeds compromise an organ's function. See Critical Site Bleed table in the Quick Reference section.","guId":"f5175785-b752-4647-9fea-9f0d614dd6b4","externalIdentifier":"3","extension":"~","expertQuestion":"<P>Life-threatening or critical site bleed?</P>","enableAgentComment":false,"defaultValue":"","dateUpdated":1603983322411,"dateUpdatedSpecified":true,"dateDeleted":"","dateCreated":1596040945758,"createdByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","comment":"","canBeModified":true,"canBeModifiedSpecified":true,"baseQuestion":"<P>Is the bleed life-threatening or at a critical site?</P>","assetType":"StandardQuestion","assetSubType":"MultipleChoiceSingleAnswer","active":true,"activeSpecified":true,"expressionField":null,"standardQuestionField":null,"standardAnswerField":null,"ReferenceLink":null},{"recommendationMediaField":null,"Items":null,"urgencyGuId":"7bdde0ae-1b45-4049-a278-ca34a5b85e7e","updatedByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","tabular":false,"sequence":0,"predictedSortingRatio":0.0,"nonVisual":true,"lowLiteracyRecommendation":"(1) Stop OAC","linkedRecommendationsOperator":"AND","linkedLanguageGuIds":"","label":"300. Stop OAC","keywords":"","active":true,"activeSpecified":true,"industryCodeGuIds":"","industryClassification":"","id":663484,"highLiteracyRecommendation":"(1) Stop OAC","helpText":"","guId":"d359bcfb-7c8f-40a0-9d84-6bb443a478a8","extension":"~","educationalInformationOnly":false,"educationalInformationOnlySpecified":true,"dateUpdated":1603990162446,"dateUpdatedSpecified":true,"dateDeleted":"","dateCreated":1596040945815,"createdByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","comment":"","canBeModified":true,"canBeModifiedSpecified":true,"averageLiteracyRecommendation":"","assetType":"Recommendation","assetSubType":"Default","externalIdentifier":"300","externalIdentifierField":"300","RecommendationMedia":null,"setName":"1"},{"recommendationMediaField":null,"Items":null,"urgencyGuId":"7bdde0ae-1b45-4049-a278-ca34a5b85e7e","updatedByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","tabular":false,"sequence":0,"predictedSortingRatio":0.0,"nonVisual":true,"lowLiteracyRecommendation":"<P>(2) Give 5-10 mg IV vitamin K.</P><P>Provide manual compression, supportive care, volume resuscitation, stop antiplatelet agent(s) if applicable, manage comorbidities, consider surgical management of bleed site.</P>","linkedRecommendationsOperator":"AND","linkedLanguageGuIds":"","label":"A. VKA Major","keywords":"","active":true,"activeSpecified":true,"industryCodeGuIds":"","industryClassification":"","id":663487,"highLiteracyRecommendation":"(2) Consider these additional steps to help control the bleed:","helpText":"","guId":"25985631-5b37-4b29-8865-b0644767b4e4","extension":"~","educationalInformationOnly":false,"educationalInformationOnlySpecified":true,"dateUpdated":1603990215730,"dateUpdatedSpecified":true,"dateDeleted":"","dateCreated":1596040945850,"createdByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","comment":"","canBeModified":true,"canBeModifiedSpecified":true,"averageLiteracyRecommendation":"<P>&bull; Give 5-10 mg IV vitamin K.</P><P>&bull; Provide local therapy/manual compression.</P><P>&bull; Provide supportive care and volume resuscitation (e.g. blood product transfusion, etc. when appropriate).</P><P>&bull; If applicable, stop antiplatelet agent(s).</P><P>&bull; Assess for and manage comorbidities that could contribute to bleeding (e.g., thrombocytopenia, uremia, liver disease).</P><P>&bull; Consider surgical/procedural management of bleeding site.</P>","assetType":"Recommendation","assetSubType":"Default","externalIdentifier":"A","externalIdentifierField":"A","RecommendationMedia":null,"setName":"2"},{"recommendationMediaField":null,"Items":null,"urgencyGuId":"7bdde0ae-1b45-4049-a278-ca34a5b85e7e","updatedByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","tabular":false,"sequence":0,"predictedSortingRatio":0.0,"nonVisual":true,"lowLiteracyRecommendation":"<P>(3) Administration of reversal agent suggested.</P><P>Administer 4F-PCC. See drug PI for dosing administration. If 4F-PCC not available, use plasma 10-15 ml/kg.</P>","linkedRecommendationsOperator":"AND","linkedLanguageGuIds":"","label":"100. Full Reversal Advice Non LT","keywords":"","active":true,"activeSpecified":true,"industryCodeGuIds":"","industryClassification":"","id":663493,"highLiteracyRecommendation":"(3) Reversal agent suggested","helpText":"","guId":"63546ecf-79d8-4e3e-b48f-4b550266132a","extension":"~","educationalInformationOnly":false,"educationalInformationOnlySpecified":true,"dateUpdated":1603990245916,"dateUpdatedSpecified":true,"dateDeleted":"","dateCreated":1596040945963,"createdByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","comment":"","canBeModified":true,"canBeModifiedSpecified":true,"averageLiteracyRecommendation":"<P><B>Administer 4F-PCC</B></P><P>&bull; See table below for appropriate dosing based on INR. </P><P>&nbsp;</P><P>B20179_Table1_HTML</P><P>† When PCCs are used to reverse vitamin K antagonists, vitamin K should also always be given.</P><P><B>&nbsp;</B></P><P><B>If 4F-PCC not available:</B></P><P>&bull; Use plasma 10-15 mL/kg.</P>","assetType":"Recommendation","assetSubType":"Default","externalIdentifier":"100","externalIdentifierField":"100","RecommendationMedia":null,"setName":"3"},{"recommendationMediaField":null,"Items":null,"urgencyGuId":"7bdde0ae-1b45-4049-a278-ca34a5b85e7e","updatedByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","tabular":false,"sequence":0,"predictedSortingRatio":0.0,"nonVisual":true,"lowLiteracyRecommendation":"(4) Consider restarting anticoagulation when patient is stable.","linkedRecommendationsOperator":"AND","linkedLanguageGuIds":"","label":"301. (4) Consider Restart","keywords":"","active":true,"activeSpecified":true,"industryCodeGuIds":"","industryClassification":"","id":663498,"highLiteracyRecommendation":"(4) Once bleed is controlled and patient is stable, consider restarting anticoagulation.","helpText":"","guId":"54106970-b317-4119-86d8-f10e1e5be15b","extension":"~","educationalInformationOnly":false,"educationalInformationOnlySpecified":true,"dateUpdated":1603990288197,"dateUpdatedSpecified":true,"dateDeleted":"","dateCreated":1596040946011,"createdByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","comment":"","canBeModified":true,"canBeModifiedSpecified":true,"averageLiteracyRecommendation":"","assetType":"Recommendation","assetSubType":"Default","externalIdentifier":"301","externalIdentifierField":"301","RecommendationMedia":null,"setName":"4"},{"updatedByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","tabular":false,"standardFooter":"true","sequence":0,"reportType":0,"reportTitle":"Report","label":"Report","keywords":"","industryCodeGuIds":"","id":663501,"helpText":"","guId":"7ccad62c-279b-4af2-8239-a584e5ed01b8","extension":"~","dateUpdated":1517592420301,"dateUpdatedSpecified":true,"dateDeleted":"","dateCreated":1596040946033,"createdByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","comment":"","canBeModified":true,"canBeModifiedSpecified":true,"assetType":"Report","assetSubType":"Default","active":true,"activeSpecified":true},{"recommendationMediaField":null,"Items":null,"urgencyGuId":"7bdde0ae-1b45-4049-a278-ca34a5b85e7e","updatedByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","tabular":false,"sequence":0,"predictedSortingRatio":0.0,"nonVisual":true,"lowLiteracyRecommendation":"<P>(3) Administration of reversal agent suggested.</P><P>Administer 4F-PCC. See drug PI for dosing administration. If 4F-PCC not available, use plasma 10-15 ml/kg.</P>","linkedRecommendationsOperator":"AND","linkedLanguageGuIds":"","label":"101. Full Reversal Advice LT","keywords":"","active":true,"activeSpecified":true,"industryCodeGuIds":"","industryClassification":"","id":663506,"highLiteracyRecommendation":"(3) Reversal agent suggested","helpText":"","guId":"cda60017-1bab-476c-b30b-393c32c592dd","extension":"~","educationalInformationOnly":false,"educationalInformationOnlySpecified":true,"dateUpdated":1603989667126,"dateUpdatedSpecified":true,"dateDeleted":"","dateCreated":1596040946088,"createdByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","comment":"","canBeModified":true,"canBeModifiedSpecified":true,"averageLiteracyRecommendation":"<P><B>Administer 4F-PCC</B></P><P>&bull; See table below for appropriate dosing based on INR.&nbsp;</P><P>&nbsp;</P><P>B20179_Table1_HTML</P><P>† When PCCs are used to reverse vitamin K antagonists, vitamin K should also always be given.</P><P>&nbsp;</P><P><B>If 4F-PCC not available:</B></P><P>&bull; Use plasma 10-15 mL/kg.</P>","assetType":"Recommendation","assetSubType":"Default","externalIdentifier":"101","externalIdentifierField":"101","RecommendationMedia":null,"setName":"3"},{"ValueCheckAnswerLink":{"variableType":"","valueCheckAnswerGuId":"e3ef4173-4003-4d7f-a2cf-a7c68ca04be8","ordering":1,"id":663518,"guId":"a7f78f3e-9d18-48ef-8bb7-edb24e6f0bb8","deletedByUserGuId":"","dateDeleted":"","assetHeaderGuId":"3bcc2a94-6dda-4063-8bd4-f124b9615cf7"},"updatedByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","tabular":false,"sequence":0,"layAnswer":"","label":"Edoxaban","keywords":"","id":663517,"helpText":"","guId":"e3ef4173-4003-4d7f-a2cf-a7c68ca04be8","extension":"~","expression":" isSelected([{1. Anticoag Selection}],\"1c. Edoxaban\")","expertAnswer":"","dateUpdated":1527264564814,"dateUpdatedSpecified":true,"dateDeleted":"","dateCreated":1596040946144,"createdByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","comment":"","canBeModified":true,"canBeModifiedSpecified":true,"baseAnswer":"Edoxaban","assetType":"ValueCheckAnswer","assetSubType":"Default","active":true,"activeSpecified":true},{"ValueCheckAnswerLink":{"variableType":"","valueCheckAnswerGuId":"bb14e3ac-4b92-4d5c-bf16-d9161c2375e0","ordering":1,"id":663520,"guId":"90f6ff9a-794f-44c1-9a88-e3d095238639","deletedByUserGuId":"","dateDeleted":"","assetHeaderGuId":"3bcc2a94-6dda-4063-8bd4-f124b9615cf7"},"updatedByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","tabular":false,"sequence":0,"layAnswer":"","label":"Dabigatran","keywords":"","id":663519,"helpText":"","guId":"bb14e3ac-4b92-4d5c-bf16-d9161c2375e0","extension":"~","expression":" isSelected([{1. Anticoag Selection}],\"1b. Dabigatran\")","expertAnswer":"","dateUpdated":1516382790832,"dateUpdatedSpecified":true,"dateDeleted":"","dateCreated":1596040946160,"createdByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","comment":"","canBeModified":true,"canBeModifiedSpecified":true,"baseAnswer":"Dabigatran","assetType":"ValueCheckAnswer","assetSubType":"Default","active":true,"activeSpecified":true},{"ValueCheckAnswerLink":{"variableType":"","valueCheckAnswerGuId":"27abe68e-be9a-43d4-a177-df1538c716f1","ordering":1,"id":663522,"guId":"8e690f99-e87a-46c8-94f6-3152eaa4dc84","deletedByUserGuId":"","dateDeleted":"","assetHeaderGuId":"3bcc2a94-6dda-4063-8bd4-f124b9615cf7"},"updatedByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","tabular":false,"sequence":0,"layAnswer":"","label":"Apixaban","keywords":"","id":663521,"helpText":"","guId":"27abe68e-be9a-43d4-a177-df1538c716f1","extension":"~","expression":" isSelected([{1. Anticoag Selection}],\"1a. Apixaban\")","expertAnswer":"","dateUpdated":1527173983764,"dateUpdatedSpecified":true,"dateDeleted":"","dateCreated":1596040946180,"createdByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","comment":"","canBeModified":true,"canBeModifiedSpecified":true,"baseAnswer":"Apixaban","assetType":"ValueCheckAnswer","assetSubType":"Default","active":true,"activeSpecified":true},{"ValueCheckAnswerLink":{"variableType":"","valueCheckAnswerGuId":"8cb7eb46-80c1-4481-a3ab-63c12cd984b2","ordering":1,"id":663524,"guId":"c12e0d5e-ba13-45f2-9ccd-9129c5736082","deletedByUserGuId":"","dateDeleted":"","assetHeaderGuId":"3bcc2a94-6dda-4063-8bd4-f124b9615cf7"},"updatedByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","tabular":false,"sequence":0,"layAnswer":"","label":"Rivaroxaban","keywords":"","id":663523,"helpText":"","guId":"8cb7eb46-80c1-4481-a3ab-63c12cd984b2","extension":"~","expression":" isSelected([{1. Anticoag Selection}],\"1d. Rivaroxaban\")","expertAnswer":"","dateUpdated":1527177017220,"dateUpdatedSpecified":true,"dateDeleted":"","dateCreated":1596040946196,"createdByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","comment":"","canBeModified":true,"canBeModifiedSpecified":true,"baseAnswer":"Rivaroxaban","assetType":"ValueCheckAnswer","assetSubType":"Default","active":true,"activeSpecified":true},{"ValueCheckAnswerLink":{"variableType":"","valueCheckAnswerGuId":"8d347042-662b-4431-b3bb-880d08878f83","ordering":1,"id":666338,"guId":"0fe6bee1-205c-473f-bdb2-244060182a91","deletedByUserGuId":"","dateDeleted":"","assetHeaderGuId":"3bcc2a94-6dda-4063-8bd4-f124b9615cf7"},"updatedByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","tabular":false,"sequence":0,"layAnswer":"","label":"Betrixaban","keywords":"","id":666336,"helpText":"","guId":"8d347042-662b-4431-b3bb-880d08878f83","extension":"~","expression":" isSelected([{1. Anticoag Selection}],\"1f. Betrixaban\")","expertAnswer":"","dateUpdated":1601933744060,"dateUpdatedSpecified":true,"dateDeleted":"","dateCreated":1601933744060,"createdByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","comment":"","canBeModified":true,"canBeModifiedSpecified":true,"baseAnswer":"Betrixaban","assetType":"ValueCheckAnswer","assetSubType":"Default","active":true,"activeSpecified":true},{"QALink":[{"questionGuId":"1983119e-7c6c-4fb4-bc43-4a4d4757c01c","ordering":3,"id":663526,"guId":"bf7cf75a-d864-47c4-b6e4-97aa6ba80c0c","expressionType":"","expressionGuId":"","deletedByUserGuId":"","dateDeleted":"","answerGuId":"e3ef4173-4003-4d7f-a2cf-a7c68ca04be8"},{"questionGuId":"1983119e-7c6c-4fb4-bc43-4a4d4757c01c","ordering":7,"id":663527,"guId":"eac7baf8-5aa7-4d77-9eee-eed60593592b","expressionType":"","expressionGuId":"","deletedByUserGuId":"","dateDeleted":"","answerGuId":"66c3572d-88c6-4813-a059-aa2ed8c37699"},{"questionGuId":"1983119e-7c6c-4fb4-bc43-4a4d4757c01c","ordering":6,"id":663528,"guId":"ba9448bb-bb4e-452b-b39c-f3cef224379d","expressionType":"","expressionGuId":"","deletedByUserGuId":"","dateDeleted":"","answerGuId":"5388f40f-a046-489a-9c8b-6af2bb5f9b34"},{"questionGuId":"1983119e-7c6c-4fb4-bc43-4a4d4757c01c","ordering":1,"id":663529,"guId":"2b20392f-a8a1-4eef-b645-e6a2eb146217","expressionType":"","expressionGuId":"","deletedByUserGuId":"","dateDeleted":"","answerGuId":"bb14e3ac-4b92-4d5c-bf16-d9161c2375e0"},{"questionGuId":"1983119e-7c6c-4fb4-bc43-4a4d4757c01c","ordering":2,"id":663530,"guId":"3ab98e76-3148-4f38-b918-52b53188cba4","expressionType":"","expressionGuId":"","deletedByUserGuId":"","dateDeleted":"","answerGuId":"27abe68e-be9a-43d4-a177-df1538c716f1"},{"questionGuId":"1983119e-7c6c-4fb4-bc43-4a4d4757c01c","ordering":4,"id":663531,"guId":"8aa30838-498e-45af-8ca1-81f445cca0af","expressionType":"","expressionGuId":"","deletedByUserGuId":"","dateDeleted":"","answerGuId":"8cb7eb46-80c1-4481-a3ab-63c12cd984b2"},{"questionGuId":"1983119e-7c6c-4fb4-bc43-4a4d4757c01c","ordering":5,"id":666340,"guId":"bb90bcb2-741a-4313-9157-5e793c194c3b","expressionType":"","expressionGuId":"","deletedByUserGuId":"","dateDeleted":"","answerGuId":"8d347042-662b-4431-b3bb-880d08878f83"}],"updatedByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","tabular":false,"showExecute":true,"sequence":0,"recordStateTimeout":"1","recordStateMeasureUnit":"Years","recordState":0,"measureUnitGuId":0,"measureTypeGuId":0,"linkedLanguageGuIds":"","layQuestion":"","label":"DOAC","keywords":"Bleed","internalTableAttribute":"","industryCodeGuIds":"","industryClassification":"","id":663525,"helpText":"","guId":"1983119e-7c6c-4fb4-bc43-4a4d4757c01c","extension":"~","expertQuestion":"","enableAgentComment":false,"dateUpdated":1601933788028,"dateUpdatedSpecified":true,"dateDeleted":"","dateCreated":1596040946209,"createdByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","comment":"","canBeModified":true,"canBeModifiedSpecified":true,"baseQuestion":"DOAC","assetType":"ValueCheckQuestion","assetSubType":"Default","active":true,"activeSpecified":true},{"recommendationMediaField":null,"Items":null,"urgencyGuId":"7bdde0ae-1b45-4049-a278-ca34a5b85e7e","updatedByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","tabular":false,"sequence":0,"predictedSortingRatio":0.0,"nonVisual":true,"lowLiteracyRecommendation":"(2) Provide manual compression, supportive care, volume resuscitation, stop antiplatelet agent(s) if applicable, manage comorbidities, consider surgical management of bleed site.","linkedRecommendationsOperator":"AND","linkedLanguageGuIds":"","label":"B. DOAC Major","keywords":"","active":true,"activeSpecified":true,"industryCodeGuIds":"","industryClassification":"","id":663536,"highLiteracyRecommendation":"(2) Consider these additional steps to help control the bleed:","helpText":"","guId":"6783018b-9eef-4507-9c10-5b5d150d0f57","extension":"~","educationalInformationOnly":false,"educationalInformationOnlySpecified":true,"dateUpdated":1603990498930,"dateUpdatedSpecified":true,"dateDeleted":"","dateCreated":1596040946278,"createdByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","comment":"","canBeModified":true,"canBeModifiedSpecified":true,"averageLiteracyRecommendation":"<P>&bull; Provide local therapy/manual compression.</P><P>&bull; Provide supportive care and volume resuscitation (e.g. blood product transfusion, etc. when appropriate).</P><P>&bull; If applicable, stop antiplatelet agent(s).</P><P>&bull; Assess for and manage comorbidities that could contribute to bleeding (e.g., thrombocytopenia, uremia, liver disease).</P><P>&bull; Consider surgical/procedural management of bleeding site.</P>","assetType":"Recommendation","assetSubType":"Default","externalIdentifier":"B","externalIdentifierField":"B","RecommendationMedia":null,"setName":"2"},{"recommendationMediaField":null,"Items":null,"urgencyGuId":"7bdde0ae-1b45-4049-a278-ca34a5b85e7e","updatedByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","tabular":false,"sequence":0,"predictedSortingRatio":0.0,"nonVisual":true,"lowLiteracyRecommendation":"<P>(3) Administration of reversal/hemostatic agent suggested. </P><P>Administer andexanet alfa; see drug PI for dosing administration. If andexanet not available, use PCC or aPCC. Consider activated charcoal for known recent ingestion (within 2-4 hours).</P>","linkedRecommendationsOperator":"AND","linkedLanguageGuIds":"","label":"109. Rivaroxaban Reversal LT","keywords":"","active":true,"activeSpecified":true,"industryCodeGuIds":"","industryClassification":"","id":663586,"highLiteracyRecommendation":"(3) Administration of reversal/hemostatic agent suggested","helpText":"","guId":"a5e51e81-2ae1-4b43-b571-f0ade0be38a7","extension":"~","educationalInformationOnly":false,"educationalInformationOnlySpecified":true,"dateUpdated":1603990836608,"dateUpdatedSpecified":true,"dateDeleted":"","dateCreated":1596040946648,"createdByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","comment":"","canBeModified":true,"canBeModifiedSpecified":true,"averageLiteracyRecommendation":"<P>B20179_Table5_HTML</P><P><SUP>II</SUP>ANNEXA-4 full report excluded patients with DOAC levels &lt;75 ng/ml because those patients were considered to have clinically insufficient levels for reversal agent. <SUP>&para</SUP>Andexanet alfa is not currently available at every institution; please refer to product locator on manufacturer&rsquo;s website. </P><P>If drug effect/level can be assessed without compromising urgent clinical care decisions, then assessment should be performed before andexanet alfa is administered.</P><P><SUP>&sect;</SUP>Refer to prescribing info for max units. To control bleeding in hemophilia patients with inhibitors, aPCC is typically administered intravenously in doses ranging from 50 U/kg to 100 U/kg, with a daily maximum of 200 U/kg. There are no randomized data regarding dosing in patients with factor Xa inhibitor&ndash;related major bleeding. Based on preclinical evidence, case reports, and case series data, an initial intravenous dose of 50 U/kg is suggested for patients with FXa inhibitor major bleeding and who are known or likely to have clinically significant anticoagulant levels.</P>","assetType":"Recommendation","assetSubType":"Default","externalIdentifier":"109","externalIdentifierField":"109","RecommendationMedia":null,"setName":"3"},{"recommendationMediaField":null,"Items":null,"urgencyGuId":"7bdde0ae-1b45-4049-a278-ca34a5b85e7e","updatedByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","tabular":false,"sequence":0,"predictedSortingRatio":0.0,"nonVisual":true,"lowLiteracyRecommendation":"<P>(3) Administration of reversal/hemostatic agent suggested.</P><P>Administer off-label treatment with high-dose andexanet alfa. If andexanet alfa unavailable, administer PCC or aPCC. Consider activated charcoal for known recent ingestion (within 2-4 hours).</P>","linkedRecommendationsOperator":"AND","linkedLanguageGuIds":"","label":"107. Edoxaban and Betrixaban Reversal LT","keywords":"","active":true,"activeSpecified":true,"industryCodeGuIds":"","industryClassification":"","id":663578,"highLiteracyRecommendation":"<P>(3) Administration of reversal/hemostatic agent suggested</P>","helpText":"","guId":"7f9fdbb2-2bcf-4d1b-ae1b-503472cc6ba5","extension":"~","educationalInformationOnly":false,"educationalInformationOnlySpecified":true,"dateUpdated":1603990321154,"dateUpdatedSpecified":true,"dateDeleted":"","dateCreated":1596040946589,"createdByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","comment":"","canBeModified":true,"canBeModifiedSpecified":true,"averageLiteracyRecommendation":"<P><B>Administer Andexanet Alfa</B></P><P>Administer off-label treatment with high-dose andexanet alfa = initial IV Bolus 800 mg at a target rate of 30 mg/min, followed by IV infusion 8 mg/min for up to 120 minutes. ANNEXA-4 full report excluded patients with DOAC levels &lt;75 ng/ml because those patients were considered to have clinically insufficient levels for reversal agent. Andexanet alfa is not currently available at every institution; please refer to product locator on manufacturers website. </P><P>&nbsp;</P><P><B>If andexanet alfa unavailable </B></P><P>Administer PCC or aPCC. Refer to prescribing info for max units. To control bleeding in hemophilia patients with inhibitors, aPCC is typically administered intravenously in doses ranging from 50 U/kg to 100 U/kg, with a daily maximum of 200 U/kg. There are no randomized data regarding dosing in patients with factor Xa inhibitorrelated major bleeding. Based on preclinical evidence, case reports, and case series data, an initial intravenous dose of 50 U/kg is suggested for patients with FXa inhibitor major bleeding and who are known or likely to have clinically significant anticoagulant levels.</P><P>&nbsp;</P><P><B>Additional Considerations </B></P><P>Consider activated charcoal for known recent ingestion (within 2-4 hours).</P>","assetType":"Recommendation","assetSubType":"Default","externalIdentifier":"107","externalIdentifierField":"107","RecommendationMedia":null,"setName":"3"},{"recommendationMediaField":null,"Items":null,"urgencyGuId":"7bdde0ae-1b45-4049-a278-ca34a5b85e7e","updatedByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","tabular":false,"sequence":0,"predictedSortingRatio":0.0,"nonVisual":true,"lowLiteracyRecommendation":"<P>(3) If these measures still do not control the bleed, then administration of a reversal/hemostatic agent is suggested.</P><P>Administer 5 g idarucizumab IV. If bleeding persists, a 2<SUP>nd</SUP> dose of idarucizumab may be reasonable.</P><P>If idarucizumab unavailable, administer PCC or aPCC 50 units/kg IV.</P><P>Consider activated charcoal for known recent ingestion (within 2-4 hours).</P>","linkedRecommendationsOperator":"AND","linkedLanguageGuIds":"","label":"103. Reversal Dabigatran Non LT","keywords":"","active":true,"activeSpecified":true,"industryCodeGuIds":"","industryClassification":"","id":663610,"highLiteracyRecommendation":"(3) If these measures still do not control the bleed, then administration of a reversal/hemostatic agent is suggested","helpText":"","guId":"d7dc78cc-4f3c-4042-9488-603ca084747e","extension":"~","educationalInformationOnly":false,"educationalInformationOnlySpecified":true,"dateUpdated":1603990546289,"dateUpdatedSpecified":true,"dateDeleted":"","dateCreated":1596040946803,"createdByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","comment":"","canBeModified":true,"canBeModifiedSpecified":true,"averageLiteracyRecommendation":"<P><B>Administer idarucizumab</B></P><P>&bull; Administer 5 g idarucizumab IV (typically provided as two separate vials each containing 2.5 g/50 mL). If bleeding persists after reversal and there is laboratory evidence of a persistent dabigatran effect, or if there is concern for a persistent anticoagulant effect before a second invasive procedure, a second dose of idarucizumab may be reasonable. </P><P>&nbsp;</P><P>&nbsp;</P><P><B>If idarucizumab is unavailable:</B></P><P>&bull; Administer PCC or aPCC. Refer to prescribing information for max units. To control bleeding in hemophilia patients with inhibitors, aPCC is typically administered intravenously in doses ranging from 50 U/kg to 100 U/kg, with a daily maximum of 200 U/kg. There are no randomized data regarding dosing in patients with factor Xa inhibitor&ndash;related major bleeding. Based on preclinical evidence, case reports, and case series data, an initial intravenous dose of 50 U/kg is suggested for patients with FXa inhibitor major bleeding and who are known or likely to have clinically significant anticoagulant levels.</P><P>&nbsp;</P><P><B>Additional Considerations</B></P><P>&bull; Consider activated charcoal for known recent ingestion (within 2-4 hours). </P>","assetType":"Recommendation","assetSubType":"Default","externalIdentifier":"103","externalIdentifierField":"103","RecommendationMedia":null,"setName":"3"},{"recommendationMediaField":null,"Items":null,"urgencyGuId":"7bdde0ae-1b45-4049-a278-ca34a5b85e7e","updatedByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","tabular":false,"sequence":0,"predictedSortingRatio":0.0,"nonVisual":true,"lowLiteracyRecommendation":"<P>(3) Administration of reversal/hemostatic agent suggested.</P><P>Administer 5 g idarucizumab IV. If bleeding persists, a 2<SUP>nd</SUP> dose of idarucizumab may be reasonable.</P><P>If idarucizumab unavailable, administer PCC or aPCC 50 units/kg IV.</P><P>Consider activated charcoal for known recent ingestion (within 2-4 hours).</P>","linkedRecommendationsOperator":"AND","linkedLanguageGuIds":"","label":"102. Reversal Dabigatran LT","keywords":"","active":true,"activeSpecified":true,"industryCodeGuIds":"","industryClassification":"","id":663542,"highLiteracyRecommendation":"(3) Administration of reversal/hemostatic agent suggested","helpText":"","guId":"daa13eaf-485e-4b10-b6db-6c86f6691a51","extension":"~","educationalInformationOnly":false,"educationalInformationOnlySpecified":true,"dateUpdated":1603997591281,"dateUpdatedSpecified":true,"dateDeleted":"","dateCreated":1596040946323,"createdByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","comment":"","canBeModified":true,"canBeModifiedSpecified":true,"averageLiteracyRecommendation":"<P><B>Administer idarucizumab</B></P><P>&bull; Administer 5 g idarucizumab IV (typically provided as two separate vials each containing 2.5 g/50 mL). For reference, in the REVERSE-AD trial, patients were treated with a fixed-dose intravenous infusion of two 2.5-gram aliquots. If bleeding persists after reversal and there is laboratory evidence of a persistent dabigatran effect, or if there is concern for a persistent anticoagulant effect before a second invasive procedure, a second dose of idarucizumab may be reasonable. </P><P>&nbsp;</P><P>&nbsp;</P><P><B>If idarucizumab is unavailable:</B></P><P>&bull; Administer PCC or aPCC. Refer to prescribing information for max units. To control bleeding in hemophilia patients with inhibitors, aPCC is typically administered intravenously in doses ranging from 50 U/kg to 100 U/kg, with a daily maximum of 200 U/kg. There are no randomized data regarding dosing in patients with factor Xa inhibitor&ndash;related major bleeding. Based on preclinical evidence, case reports, and case series data, an initial intravenous dose of 50 U/kg is suggested for patients with FXa inhibitor major bleeding and who are known or likely to have clinically significant anticoagulant levels.</P><P>&nbsp;</P><P><B>Additional Considerations</B></P><P>&bull; Consider activated charcoal for known recent ingestion (within 2-4 hours). </P>","assetType":"Recommendation","assetSubType":"Default","externalIdentifier":"102","externalIdentifierField":"102","RecommendationMedia":null,"setName":"3"},{"recommendationMediaField":null,"Items":null,"urgencyGuId":"7bdde0ae-1b45-4049-a278-ca34a5b85e7e","updatedByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","tabular":false,"sequence":0,"predictedSortingRatio":0.0,"nonVisual":true,"lowLiteracyRecommendation":"<P>(3) If these measures still do not control the bleed, then administration of a reversal/hemostatic agent is suggested.</P><P>Administer andexanet alfa; see drug PI for dosing administration. If andexanet not available, use PCC or aPCC. Consider activated charcoal for known recent ingestion (within 2-4 hours).</P>","linkedRecommendationsOperator":"AND","linkedLanguageGuIds":"","label":"104. Apixaban Reversal Non LT","keywords":"","active":true,"activeSpecified":true,"industryCodeGuIds":"","industryClassification":"","id":663560,"highLiteracyRecommendation":"(3) If these measures still do not control the bleed, then administration of a reversal/hemostatic agent is suggested.","helpText":"","guId":"ba0ac0f7-2589-4691-8eab-da54c90c8b64","extension":"~","educationalInformationOnly":false,"educationalInformationOnlySpecified":true,"dateUpdated":1603996821263,"dateUpdatedSpecified":true,"dateDeleted":"","dateCreated":1596040946449,"createdByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","comment":"","canBeModified":true,"canBeModifiedSpecified":true,"averageLiteracyRecommendation":"<P>B20179_Table4_HTML</P><P>&nbsp;<SUP>II</SUP>ANNEXA-4 full report excluded patients with DOAC levels &lt;75 ng/ml because those patients were considered to have clinically insufficient levels for reversal agent. <SUP>&para</SUP>Andexanet alfa is not currently available at every institution; please refer to product locator on manufacturer&rsquo;s website. </P><P>If drug effect/level can be assessed without compromising urgent clinical care decisions, then assessment should be performed before andexanet alfa is administered.</P><P><SUP>&sect;</SUP>Refer to prescribing info for max units.To control bleeding in hemophilia patients with inhibitors, aPCC is typically administered intravenously in doses ranging from 50 U/kg to 100 U/kg, with a daily maximum of 200 U/kg. There are no randomized data regarding dosing in patients with factor Xa inhibitor&ndash;related major bleeding. Based on preclinical evidence, case reports, and case series data, an initial intravenous dose of 50 U/kg is suggested for patients with FXa inhibitor major bleeding and who are known or likely to have clinically significant anticoagulant levels.</P>","assetType":"Recommendation","assetSubType":"Default","externalIdentifier":"104","externalIdentifierField":"104","RecommendationMedia":null,"setName":"3"},{"recommendationMediaField":null,"Items":null,"urgencyGuId":"7bdde0ae-1b45-4049-a278-ca34a5b85e7e","updatedByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","tabular":false,"sequence":0,"predictedSortingRatio":0.0,"nonVisual":true,"lowLiteracyRecommendation":"<P>(3) If these measures still do not control the bleed, then administration of a reversal/hemostatic agent is suggested.</P><P>Administer off-label treatment with high-dose andexanet alfa. See drug PI for dosing administration.If andexanet alfa unavailable, administer PCC or aPCC. Consider activated charcoal for known recent ingestion (within 2-4 hours).</P>","linkedRecommendationsOperator":"AND","linkedLanguageGuIds":"","label":"106. Edoxaban and Betrixaban Reversal Non LT","keywords":"","active":true,"activeSpecified":true,"industryCodeGuIds":"","industryClassification":"","id":663553,"highLiteracyRecommendation":"(3) If these measures still do not control the bleed, then administration of a reversal/hemostatic agent is suggested.","helpText":"","guId":"13a1b7e2-0eee-47ce-b2b6-fc455f8be822","extension":"~","educationalInformationOnly":false,"educationalInformationOnlySpecified":true,"dateUpdated":1603990128357,"dateUpdatedSpecified":true,"dateDeleted":"","dateCreated":1596040946404,"createdByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","comment":"","canBeModified":true,"canBeModifiedSpecified":true,"averageLiteracyRecommendation":"<P><B>Administer Andexanet Alfa</B></P><P>Administer off-label treatment with high-dose andexanet alfa = initial IV Bolus 800 mg at a target rate of 30 mg/min, followed by IV infusion 8 mg/min for up to 120 minutes. ANNEXA-4 full report excluded patients with DOAC levels &lt;75 ng/ml because those patients were considered to have clinically insufficient levels for reversal agent. Andexanet alfa is not currently available at every institution; please refer to product locator on manufacturers website. </P><P>&nbsp;</P><P><B>If andexanet alfa unavailable </B></P><P>Administer PCC or aPCC. Refer to prescribing info for max units. To control bleeding in hemophilia patients with inhibitors, aPCC is typically administered intravenously in doses ranging from 50 U/kg to 100 U/kg, with a daily maximum of 200 U/kg. There are no randomized data regarding dosing in patients with factor Xa inhibitorrelated major bleeding. Based on preclinical evidence, case reports, and case series data, an initial intravenous dose of 50 U/kg is suggested for patients with FXa inhibitor major bleeding and who are known or likely to have clinically significant anticoagulant levels.</P><P>&nbsp;</P><P><B>Additional Considerations </B></P><P>Consider activated charcoal for known recent ingestion (within 2-4 hours).</P>","assetType":"Recommendation","assetSubType":"Default","externalIdentifier":"106","externalIdentifierField":"106","RecommendationMedia":null,"setName":"3"},{"recommendationMediaField":null,"Items":null,"urgencyGuId":"7bdde0ae-1b45-4049-a278-ca34a5b85e7e","updatedByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","tabular":false,"sequence":0,"predictedSortingRatio":0.0,"nonVisual":true,"lowLiteracyRecommendation":"<P>(3) If these measures still do not control the bleed, then administration of a reversal/hemostatic agent is suggested.</P><P>Administer andexanet alfa; see drug PI for dosing administration. If andexanet not available, use PCC or aPCC. </P><P>Consider activated charcoal for known recent ingestion (within 2-4 hours).</P>","linkedRecommendationsOperator":"AND","linkedLanguageGuIds":"","label":"108. Rivaroxaban Reversal Non LT","keywords":"","active":true,"activeSpecified":true,"industryCodeGuIds":"","industryClassification":"","id":663567,"highLiteracyRecommendation":"(3) If these measures still do not control the bleed, then administration of a reversal/hemostatic agent is suggested.","helpText":"","guId":"9a6d0896-5aa2-4bca-848d-d34187120551","extension":"~","educationalInformationOnly":false,"educationalInformationOnlySpecified":true,"dateUpdated":1603996843975,"dateUpdatedSpecified":true,"dateDeleted":"","dateCreated":1596040946506,"createdByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","comment":"","canBeModified":true,"canBeModifiedSpecified":true,"averageLiteracyRecommendation":"<P>B20179_Table5_HTML</P><P>&nbsp;<SUP>II</SUP>ANNEXA-4 full report excluded patients with DOAC levels &lt;75 ng/ml because those patients were considered to have clinically insufficient levels for reversal agent. <SUP>&para</SUP>Andexanet alfa is not currently available at every institution; please refer to product locator on manufacturer&rsquo;s website. </P><P>If drug effect/level can be assessed without compromising urgent clinical care decisions, then assessment should be performed before andexanet alfa is administered.</P><P><SUP>&sect;</SUP>Refer to prescribing info for max units.To control bleeding in hemophilia patients with inhibitors, aPCC is typically administered intravenously in doses ranging from 50 U/kg to 100 U/kg, with a daily maximum of 200 U/kg. There are no randomized data regarding dosing in patients with factor Xa inhibitor&ndash;related major bleeding. Based on preclinical evidence, case reports, and case series data, an initial intravenous dose of 50 U/kg is suggested for patients with FXa inhibitor major bleeding and who are known or likely to have clinically significant anticoagulant levels.</P>","assetType":"Recommendation","assetSubType":"Default","externalIdentifier":"108","externalIdentifierField":"108","RecommendationMedia":null,"setName":"3"},{"recommendationMediaField":null,"Items":null,"urgencyGuId":"7bdde0ae-1b45-4049-a278-ca34a5b85e7e","updatedByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","tabular":false,"sequence":0,"predictedSortingRatio":0.0,"nonVisual":true,"lowLiteracyRecommendation":"<P>(3) Administration of reversal/hemostatic agent suggested. </P><P>Administer andexanet alfa; see drug PI for dosing administration. If andexanet not available, use PCC or aPCC. Consider activated charcoal for known recent ingestion (within 2-4 hours).</P>","linkedRecommendationsOperator":"AND","linkedLanguageGuIds":"","label":"105. Apixaban Reversal LT","keywords":"","active":true,"activeSpecified":true,"industryCodeGuIds":"","industryClassification":"","id":663593,"highLiteracyRecommendation":"(3) Administration of reversal/hemostatic agent suggested","helpText":"","guId":"9e7e9da0-e3a6-4977-8a86-05b32c2a925b","extension":"~","educationalInformationOnly":false,"educationalInformationOnlySpecified":true,"dateUpdated":1603996801371,"dateUpdatedSpecified":true,"dateDeleted":"","dateCreated":1596040946693,"createdByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","comment":"","canBeModified":true,"canBeModifiedSpecified":true,"averageLiteracyRecommendation":"<P>B20179_Table4_HTML</P><P><SUP>II</SUP>ANNEXA-4 full report excluded patients with DOAC levels &lt;75 ng/ml because those patients were considered to have clinically insufficient levels for reversal agent. <SUP>&para</SUP>Andexanet alfa is not currently available at every institution; please refer to product locator on manufacturer&rsquo;s website. </P><P>If drug effect/level can be assessed without compromising urgent clinical care decisions, then assessment should be performed before andexanet alfa is administered.</P><P><SUP>&sect;</SUP>Refer to prescribing info for max units. To control bleeding in hemophilia patients with inhibitors, aPCC is typically administered intravenously in doses ranging from 50 U/kg to 100 U/kg, with a daily maximum of 200 U/kg. There are no randomized data regarding dosing in patients with factor Xa inhibitor&ndash;related major bleeding. Based on preclinical evidence, case reports, and case series data, an initial intravenous dose of 50 U/kg is suggested for patients with FXa inhibitor major bleeding and who are known or likely to have clinically significant anticoagulant levels.</P>","assetType":"Recommendation","assetSubType":"Default","externalIdentifier":"105","externalIdentifierField":"105","RecommendationMedia":null,"setName":"3"},{"weightValue":"N/A","label":"9a. Yes","updatedByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","tabular":false,"expertQuestion":null,"showImageLabel":true,"sequence":0,"mediaGuId":"","layAnswer":"","keywords":"","id":663619,"helpText":"","guId":"ed9e44c6-bf4c-423a-9de6-d596cf9b6e07","externalIdentifier":"9a","extension":"~","expertAnswer":"Yes","dateUpdated":1603983275174,"dateUpdatedSpecified":true,"dateDeleted":"","dateCreated":1596040946844,"createdByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","comment":"","canBeModified":true,"canBeModifiedSpecified":true,"baseAnswer":"Yes","assetType":"StandardAnswer","assetSubType":"MultipleChoice","active":true,"activeSpecified":true,"exclusive":false,"Expression":null,"referenceLinkField":null},{"weightValue":"N/A","label":"9b. No","updatedByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","tabular":false,"expertQuestion":null,"showImageLabel":true,"sequence":0,"mediaGuId":"","layAnswer":"","keywords":"","id":663620,"helpText":"","guId":"60b5cf96-0620-45eb-abc4-a6384ce10c79","externalIdentifier":"9b","extension":"~","expertAnswer":"No","dateUpdated":1603983284768,"dateUpdatedSpecified":true,"dateDeleted":"","dateCreated":1596040946852,"createdByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","comment":"","canBeModified":true,"canBeModifiedSpecified":true,"baseAnswer":"No","assetType":"StandardAnswer","assetSubType":"MultipleChoice","active":true,"activeSpecified":true,"exclusive":false,"Expression":null,"referenceLinkField":null},{"StandardQuestion":null,"StandardAnswer":null,"Expression":null,"QALink":[{"questionGuId":"56993c2a-46f9-4357-b88e-e08ba0bb2e27","ordering":4,"id":663622,"guId":"6f4cc2a9-6781-49ba-9082-09719c271733","expressionType":"Show","expressionGuId":"","deletedByUserGuId":"","dateDeleted":"","answerGuId":"9a574412-384c-41b4-98b1-22b77bf7fd3d"},{"questionGuId":"56993c2a-46f9-4357-b88e-e08ba0bb2e27","ordering":3,"id":663623,"guId":"b77275a5-f4a2-4ec9-ad0d-8ced4412b59f","expressionType":"Show","expressionGuId":"","deletedByUserGuId":"","dateDeleted":"","answerGuId":"5756cbdf-81b7-4415-8ab1-5d398d3edb12"},{"questionGuId":"56993c2a-46f9-4357-b88e-e08ba0bb2e27","ordering":1,"id":663624,"guId":"af1e09db-a666-4e13-9558-dc49b4b20a96","expressionType":"Show","expressionGuId":"","deletedByUserGuId":"","dateDeleted":"","answerGuId":"ed9e44c6-bf4c-423a-9de6-d596cf9b6e07"},{"questionGuId":"56993c2a-46f9-4357-b88e-e08ba0bb2e27","ordering":2,"id":663625,"guId":"c7449be6-60bf-49b4-9432-a0062fe3a1b3","expressionType":"Show","expressionGuId":"","deletedByUserGuId":"","dateDeleted":"","answerGuId":"60b5cf96-0620-45eb-abc4-a6384ce10c79"}],"updatedByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","tabular":false,"showExecute":true,"sequence":0,"recordStateTimeout":1,"recordStateMeasureUnit":"Years","recordState":0,"measureTypeGuId":0,"linkedLanguageGuIds":"","layQuestion":"","label":"9. Does Bleed Require Hospitalization?","keywords":"Bleed","internalTableAttribute":"","industryCodeGuIds":"","industryClassification":"","id":663621,"helpText":"","guId":"56993c2a-46f9-4357-b88e-e08ba0bb2e27","externalIdentifier":"9","extension":"~","expertQuestion":"Does the bleed require hospitalization, surgical/procedural intervention, or transfusion?","enableAgentComment":false,"defaultValue":"","dateUpdated":1603983287433,"dateUpdatedSpecified":true,"dateDeleted":"","dateCreated":1596040946862,"createdByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","comment":"","canBeModified":true,"canBeModifiedSpecified":true,"baseQuestion":"Does the bleed require hospitalization, surgical/procedural intervention, or transfusion?","assetType":"StandardQuestion","assetSubType":"MultipleChoiceSingleAnswer","active":true,"activeSpecified":true,"expressionField":null,"standardQuestionField":null,"standardAnswerField":null,"ReferenceLink":null},{"recommendationMediaField":null,"Items":null,"urgencyGuId":"7bdde0ae-1b45-4049-a278-ca34a5b85e7e","updatedByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","tabular":false,"sequence":0,"predictedSortingRatio":0.0,"nonVisual":true,"lowLiteracyRecommendation":"<P>(2) Consider 2-5 mg PO/IV vitamin K.</P><P>Provide manual compression, supportive care, stop antiplatelet agent(s) if applicable, manage comorbidities, consider surgical management of bleed site.</P>","linkedRecommendationsOperator":"AND","linkedLanguageGuIds":"","label":"C. VKA Non-Major","keywords":"","active":true,"activeSpecified":true,"industryCodeGuIds":"","industryClassification":"","id":663661,"highLiteracyRecommendation":"<P>(2) Consider these additional steps to help control the bleed:</P>","helpText":"","guId":"428cf500-cb15-4149-89c4-7fa976352659","extension":"~","educationalInformationOnly":false,"educationalInformationOnlySpecified":true,"dateUpdated":1603989916079,"dateUpdatedSpecified":true,"dateDeleted":"","dateCreated":1596040947153,"createdByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","comment":"","canBeModified":true,"canBeModifiedSpecified":true,"averageLiteracyRecommendation":"<P>&bull; Consider 2-5 mg PO/IV vitamin K.</P><P>&bull; Provide local therapy/manual compression.</P><P>&bull; Provide supportive care and volume resuscitation (e.g. blood product transfusion, etc. when appropriate).</P><P>&bull; If applicable, stop antiplatelet agent(s).</P><P>&bull; Assess for and manage comorbidities that could contribute to bleeding (e.g. thrombocytopenia, uremia, liver disease).</P><P>&bull; Consider surgical/procedural management of bleeding site.</P>","assetType":"Recommendation","assetSubType":"Default","externalIdentifier":"C","externalIdentifierField":"C","RecommendationMedia":null,"setName":"2"},{"recommendationMediaField":null,"Items":null,"urgencyGuId":"7bdde0ae-1b45-4049-a278-ca34a5b85e7e","updatedByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","tabular":false,"sequence":0,"predictedSortingRatio":0.0,"nonVisual":true,"lowLiteracyRecommendation":"(3) Consider restarting anticoagulation when patient is stable.","linkedRecommendationsOperator":"AND","linkedLanguageGuIds":"","label":"302. (3) Consider Restart","keywords":"","active":true,"activeSpecified":true,"industryCodeGuIds":"","industryClassification":"","id":663638,"highLiteracyRecommendation":"(3) Once bleed is controlled and patient is stable, consider restarting anticoagulation.","helpText":"","guId":"d9c3cec3-8529-4e69-81d0-91b10edda8a8","extension":"~","educationalInformationOnly":false,"educationalInformationOnlySpecified":true,"dateUpdated":1603990605479,"dateUpdatedSpecified":true,"dateDeleted":"","dateCreated":1596040946987,"createdByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","comment":"","canBeModified":true,"canBeModifiedSpecified":true,"averageLiteracyRecommendation":"","assetType":"Recommendation","assetSubType":"Default","externalIdentifier":"302","externalIdentifierField":"302","RecommendationMedia":null,"setName":"3"},{"recommendationMediaField":null,"Items":null,"urgencyGuId":"7bdde0ae-1b45-4049-a278-ca34a5b85e7e","updatedByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","tabular":false,"sequence":0,"predictedSortingRatio":0.0,"nonVisual":true,"lowLiteracyRecommendation":"(2) Provide manual compression, assess risks and benefits of stopping concomitant antiplatelet therapy, manage comorbidities, reassess OAC dosing.","linkedRecommendationsOperator":"AND","linkedLanguageGuIds":"","label":"D. VKA Non-Major","keywords":"","active":true,"activeSpecified":true,"industryCodeGuIds":"","industryClassification":"","id":663673,"highLiteracyRecommendation":"<P>(2) Consider these additional steps to help control the bleed:</P>","helpText":"","guId":"eed79a64-199a-41ea-8f9a-56995d065388","extension":"~","educationalInformationOnly":false,"educationalInformationOnlySpecified":true,"dateUpdated":1603990338051,"dateUpdatedSpecified":true,"dateDeleted":"","dateCreated":1596040947224,"createdByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","comment":"","canBeModified":true,"canBeModifiedSpecified":true,"averageLiteracyRecommendation":"<P>&bull; Provide local therapy/manual compression.</P><P>&bull; If patient is on concomitant antiplatelet therapy, assess risks and benefits of stopping.</P><P>&bull; Assess for and manage comorbidities that could contribute to bleeding (e.g. thrombocytopenia, uremia, liver disease).</P><P>&bull; Determine if dosing of OAC is appropriate.</P>","assetType":"Recommendation","assetSubType":"Default","externalIdentifier":"D","externalIdentifierField":"D","RecommendationMedia":null,"setName":"2"},{"recommendationMediaField":null,"Items":null,"urgencyGuId":"7bdde0ae-1b45-4049-a278-ca34a5b85e7e","updatedByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","tabular":false,"sequence":0,"predictedSortingRatio":0.0,"nonVisual":true,"lowLiteracyRecommendation":"<P>(1) Continue OAC if appropriate</P>","linkedRecommendationsOperator":"AND","linkedLanguageGuIds":"","label":"303. Continue OAC","keywords":"","active":true,"activeSpecified":true,"industryCodeGuIds":"","industryClassification":"","id":663650,"highLiteracyRecommendation":"<P>(1) Consider continuing OAC (provided there is an appropriate indication)</P>","helpText":"","guId":"4ee3605c-a53c-451c-8aa2-e575ff94c00d","extension":"~","educationalInformationOnly":false,"educationalInformationOnlySpecified":true,"dateUpdated":1603990417155,"dateUpdatedSpecified":true,"dateDeleted":"","dateCreated":1596040947084,"createdByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","comment":"","canBeModified":true,"canBeModifiedSpecified":true,"averageLiteracyRecommendation":"","assetType":"Recommendation","assetSubType":"Default","externalIdentifier":"303","externalIdentifierField":"303","RecommendationMedia":null,"setName":"1"},{"recommendationMediaField":null,"Items":null,"urgencyGuId":"7bdde0ae-1b45-4049-a278-ca34a5b85e7e","updatedByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","tabular":false,"sequence":0,"predictedSortingRatio":0.0,"nonVisual":true,"lowLiteracyRecommendation":"<P>(1) Stop OAC. Do not administer reversal agent.</P>","linkedRecommendationsOperator":"AND","linkedLanguageGuIds":"","label":"304. Stop OAC do not admin reversal agent","keywords":"","active":true,"activeSpecified":true,"industryCodeGuIds":"","industryClassification":"","id":663628,"highLiteracyRecommendation":"<P>(1) Stop OAC. Do not administer reversal agent.</P>","helpText":"","guId":"f2ae5926-d91a-412f-925c-84b40f4b34eb","extension":"~","educationalInformationOnly":false,"educationalInformationOnlySpecified":true,"dateUpdated":1603995134707,"dateUpdatedSpecified":true,"dateDeleted":"","dateCreated":1596040946926,"createdByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","comment":"","canBeModified":true,"canBeModifiedSpecified":true,"averageLiteracyRecommendation":"","assetType":"Recommendation","assetSubType":"Default","externalIdentifier":"304","externalIdentifierField":"304","RecommendationMedia":null,"setName":"1"},{"recommendationMediaField":null,"Items":null,"urgencyGuId":"7bdde0ae-1b45-4049-a278-ca34a5b85e7e","updatedByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","tabular":false,"sequence":0,"predictedSortingRatio":0.0,"nonVisual":true,"lowLiteracyRecommendation":"(2) Provide manual compression, supportive care, volume resuscitation, stop antiplatelet agent(s) if applicable, manage comorbidities, consider surgical management of bleed site.","linkedRecommendationsOperator":"AND","linkedLanguageGuIds":"","label":"E. DOAC Non-Major","keywords":"","active":true,"activeSpecified":true,"industryCodeGuIds":"","industryClassification":"","id":663633,"highLiteracyRecommendation":"<P>(2) Consider these additional steps to help control the bleed:</P>","helpText":"","guId":"addd4542-1172-4ccc-8f25-8ca4ae1ad810","extension":"~","educationalInformationOnly":false,"educationalInformationOnlySpecified":true,"dateUpdated":1603995020682,"dateUpdatedSpecified":true,"dateDeleted":"","dateCreated":1596040946963,"createdByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","comment":"","canBeModified":true,"canBeModifiedSpecified":true,"averageLiteracyRecommendation":"<P>&bull; Provide local therapy/manual compression.</P><P>&bull; Provide supportive care and volume resuscitation (e.g. blood product transfusion, etc. when appropriate).</P><P>&bull; If applicable, stop antiplatelet agent(s).</P><P>&bull; Assess for and manage comorbidities that could contribute to bleeding (e.g. thrombocytopenia, uremia, liver disease).</P><P>&bull; Consider surgical/procedural management of bleeding site.</P>","assetType":"Recommendation","assetSubType":"Default","externalIdentifier":"E","externalIdentifierField":"E","RecommendationMedia":null,"setName":"2"},{"recommendationMediaField":null,"Items":null,"urgencyGuId":"7bdde0ae-1b45-4049-a278-ca34a5b85e7e","updatedByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","tabular":false,"sequence":0,"predictedSortingRatio":0.0,"nonVisual":true,"lowLiteracyRecommendation":"(2) Provide manual compression, assess risks and benefits of stopping concomitant antiplatelet therapy, manage comorbidities, reassess OAC dosing.","linkedRecommendationsOperator":"AND","linkedLanguageGuIds":"","label":"F. DOAC Non-Major","keywords":"","active":true,"activeSpecified":true,"industryCodeGuIds":"","industryClassification":"","id":663645,"highLiteracyRecommendation":"<P>(2) Consider these additional steps to help control the bleed:</P>","helpText":"","guId":"2666fd57-6fc4-474e-b277-a0d437f0dcc7","extension":"~","educationalInformationOnly":false,"educationalInformationOnlySpecified":true,"dateUpdated":1603990717707,"dateUpdatedSpecified":true,"dateDeleted":"","dateCreated":1596040947035,"createdByUserGuId":"8f4267dc-5cad-4b7d-8004-e24273ab017d","comment":"","canBeModified":true,"canBeModifiedSpecified":true,"averageLiteracyRecommendation":"<P>&bull; Provide local therapy/manual compression.</P><P>&bull; If patient is on concomitant antiplatelet therapy, assess risks and benefits of stopping.</P><P>&bull; Assess for and manage comorbidities that could contribute to bleeding (e.g. thrombocytopenia, uremia, liver disease).</P><P>&bull; Determine if dosing of OAC is appropriate.</P>","assetType":"Recommendation","assetSubType":"Default","externalIdentifier":"F","externalIdentifierField":"F","RecommendationMedia":null,"setName":"2"}];

    //Get json of Enum for reuse
    var assetType = {"Algorithm":"Algorithm","Action":"Action","Calculation":"Calculation","CalculationAnswer":"CalculationAnswer","StandardQuestion":"StandardQuestion","StandardAnswer":"StandardAnswer","Recommendation":"Recommendation","ExpressionAnswer":"ExpressionAnswer","Expression":"Expression","ValueQuestion":"ValueQuestion","ValueCheckQuestion":"ValueCheckQuestion","IntegrationServiceAction":"IntegrationServiceAction","SubPoint":"SubPoint","ValueAnswer":"ValueAnswer","ValueSet":"ValueSet","Message":"Message","Report":"Report","TextAnswer":"TextAnswer","TextQuestion":"TextQuestion","Action1":"Action1","WeightedAnswer":"WeightedAnswer","WeightedQuestion":"WeightedQuestion","WeightedQuestionLink":"WeightedQuestionLink","ValueCheckAnswer":"ValueCheckAnswer","Form":"Form"};
    var assetSubType = {"Default":"Default","MultipleChoiceMultipleAnswersCoded":"MultipleChoiceMultipleAnswersCoded","MultipleChoiceSingleAnswerCoded":"MultipleChoiceSingleAnswerCoded","MultipleChoiceCodedAnswer":"MultipleChoiceCodedAnswer","General":"General","MultipleChoice":"MultipleChoice","MultipleChoiceLikertScale":"MultipleChoiceLikertScale","MultipleChoiceSingleAnswer":"MultipleChoiceSingleAnswer","MultipleChoiceMultipleAnswers":"MultipleChoiceMultipleAnswers","YesNo":"YesNo","Alert":"Alert","Instruction":"Instruction","Information":"Information","Intervention":"Intervention"};

    var formQuestionCount;
    var targetRule = rulesJson[0].targetRule;
    var firstAsset = '';
    var firstTargetRule = '';
    $(function() {

                formQuestionCount=0;

        standardQuestionExpression = [];
        standardQuestionsList = [];
        standardAnswerList = [];
        //Adding standard question expression into asset node
        assetNode = assetNode.concat(standardQuestionExpression);
        assetNode = assetNode.concat(standardQuestionsList);
        assetNode = assetNode.concat(standardAnswerList);
        firstAsset = '3bcc2a94-6dda-4063-8bd4-f124b9615cf7';
        targetRule = 'fa0951ac-8a06-4d2b-88f9-27d4d4234bea';
        firstTargetRule = targetRule;
        isRecommendation = 'False';
        isRecommendation = (isRecommendation.toLowerCase() == 'true') ? true : false;
        isForm = 'False';
        isForm = (isForm.toLowerCase() == 'true') ? true : false;

        isQueryStringOn = true;
        if(isRecommendation){
            utils.appendRecommendationCard(firstAsset);
            evaluateTargetRule(firstAsset, '');
        }else{
            if(isForm) {
                evaluateForm(firstAsset);
            }
            else
                utils.appendQuestionCard(firstAsset);
        }
        isQueryStringOn = false;
        pageScrollTop();
        /*Added the code for calculating min height of a page so as to remove white spacing below footer*/
        var view = viewHeight();
        mh = (view - 169);
        $(".fullscreen-spacer").css("min-height", mh);
        $(window).resize(function () {
            mh = (view - 169);
            $(".fullscreen-spacer").css("min-height", mh);
        });
        queryStringParser();
    });


    var htmlTemplatesAP = {
        "4FPCC_HTML": "<table class='table' style='font-size: 1em'><thead><tr>                                                   <th>INR</th>                                                    <th>4F-PCC Dose</th>                                                </tr>                                            </thead>                                            <tbody>                                                <tr>                                                    <td>INR &lt; 2</td>                                                    <td>4F-PCC Not approved; use clinical judgement. </td>                                                </tr>                                                <tr>                                                    <td>INR &ge; 2 and &lt; 4</td>                                                    <td>Administer 25 units/kg</td>                                                </tr>                                                <tr>                                                    <td>INR 4 - 6</td>                                                    <td>Administer 35 units/kg</td>                                                </tr>                                                <tr>                                                   <td>INR &gt; 6</td>                                                    <td>Administer 50 units/kg</td>                                                </tr>                                                <tr>                                                    <td>INR Unavailable</td>                                                    <td>4F-PCC low fixed-dose option:                                                        <ul>                                                            <li>1000 units for any major bleed</li>                                                            <li>1500 units for intracranial hemorrhage</li>                                                        </ul>                                                    </td>                                               </tr>                                                <tr>                                                    <td colspan='2'>Max dose 5,000 units capped at 100 kg body weight</td>                                                </tr>                                            </tbody>                                        </table> ",
         "andexanet_apixaban": "<table class='table' style='font-size: 1em'><thead><tr class='custom-success'><td colspan='2'>Last apixaban dose</td> <td colspan='6' style='color: #ffffff;' >Timing of last apixaban dose before andexanet alfa initiation</td></tr>  </thead><tbody><tr><td colspan='2'></td> <td class='middle-banded' colspan='3' ><b>&lt; 8 hours ago or unknown<b></td> <td class='middle-banded' colspan='3' > &ge;<b> 8 hours ago</b></td></tr><tr><td class='middle-banded' colspan='2'>&le;<b> 5 mg</b></td> <td colspan='6'><b>Administer low dose of andexanet alfa</b><br/> <ul><li>Initial IV Bolus: 400 mg at a target rate of 30 mg/min</li><li>Follow-on IV Infusion: 4 mg/min for up to 120 minutes</li></ul></td></tr>  <tr><td class='middle-banded' colspan='2' ><b>&gt; 5 mg/unknown</b></td><td colspan='3'><b>Administer high dose of andexanet alfa</b><ul><li>Initial IV Bolus: 800 mg at a target rate of 30 mg/min</li><li>Follow-on IV Infusion: 8 mg/min for up to 120 minutes</li></ul></td> <td colspan='3'><b>Administer low dose of andexanet alfa</b><ul><li>Initial IV Bolus: 400 mg at a target rate of 30 mg/min</li><li>Follow-on IV Infusion: 4 mg/min for up to 120 minutes</li></ul></td></tr>           </tbody>                                                      </table>",
        "andexanet_rivaroxaban": "<table class='table' style='font-size: 1em'><thead><tr class='custom-success'><td colspan='2'>Last rivaroxaban dose</td> <td colspan='6' style='color: #ffffff;' >Timing of last rivaroxaban dose before andexanet alfa initiation</td></tr>  </thead><tr><td colspan='2'></td> <td class='middle-banded' colspan='3'><b>&lt; 8 hours ago or unknown</b></td> <td class='middle-banded' colspan='3'> &ge; <b>8 hours ago</b></td></tr><tr><td class='middle-banded' colspan='2'><b>&le; 10 mg</b></td> <td colspan='6'><b>Administer low dose of andexanet alfa</b><br/> <ul><li>Initial IV Bolus: 400 mg at a target rate of 30 mg/min</li><li>Follow-on IV Infusion: 4 mg/min for up to 120 minutes</li></ul></td></tr>  <tr><td class='middle-banded' colspan='2'><b>&gt; 10 mg/unknown</b></td><td colspan='3'><b>Administer high dose of andexanet alfa</b> <ul><li>Initial IV Bolus: 800 mg at a target rate of 30 mg/min</li><li>Follow-on IV Infusion: 8 mg/min for up to 120 minutes</li></ul></td> <td colspan='3'><b>Administer low dose of andexanet alfa<ul><li>Initial IV Bolus: 400 mg at a target rate of 30 mg/min</li><li>Follow-on IV Infusion: 4 mg/min for up to 120 minutes</li></ul></b></td></tr>                                                                 </table>",

        "B20179_Table1_HTML": "<table class='table' style='font-size: 1em' border='1'><thead><tr class='custom-success'><td colspan='3'><center><b>Vitamin K Antagonists (warfarin)</b></center></td></tr><tr class='custom-success-secondary'><td><b>Reversal Stratergy</b></td><td colspan='2'><b>Dosage</b></td></tr></thead><tbody><tr class='gray-bg'><td style='width: 33%;'>4F-PCC<sup>†</sup></td><td style='width: 33%;'>&nbsp;</td><td rowspan='6' style='width: 33%;' class='white-bg'> <b>Note regarding vitamin K:</b><br> When PCCs are used to reverse VKAs, vitamin K should always be given.<br><br> If bleed is considered <b>major:</b> Administer 5-10 mg IV vitamin K<br><br> If bleed is considered <b>nonmajor:</b> Administer 2-5 mg PO/IV vitamin K</td></tr><tr class='gray-bg'><td>&bull; INR 2 to &lt; 4</td><td>25 units/kg</td></tr><tr class='gray-bg'><td>&bull; INR 4-6</td><td>35 units/kg</td></tr><tr class='gray-bg'><td>&bull; INR &gt;6</td><td>50 units/kg</td></tr><tr class='gray-bg'><td rowspan='2'>4F-PCC low fixed-dose option</td><td>1000 units for any non-intractional major bleed</td></tr><tr class='gray-bg'><td>1500 units for intrational hemorrhage</td></tr><tr class='gray-bg'><td>If 4F-PCC not available, administer plasma</td><td colspan='2'>10-15 mL/kg (1)</td></tr></tbody></table>",

        "B20179_Table4_HTML": "<div class='table-wrapper'><table class='table table-scroll' style='font-size: 1em' border='1'><thead><tr class='custom-success'><td colspan='6'><center><b>Factor Xa Inhibitator (apixaban)</b></center></td></tr><tr class='custom-success-secondary'><td style='width: 40%;' colspan='3'><b>Reversal Stratergy</b></td><td colspan='3' style='width: 60%;'><b>Dosage</b></td></tr></thead><tbody><tr><td rowspan='5' class='gray-bg text-mid' style='width: 10%;' valign='middle'>Andexanet alfa <sup>&quot;¶</sup></td><td class='custom-success-lgtbg text-mid' style='width: 10%;'>Last dose of apixaban</td><td class='custom-success-lgtbg text-mid' style='width: 20%;'>Timing of last dose</td><td class='custom-success-lgtbg text-mid' style='width: 10%;'>Low/High</td><td class='custom-success-lgtbg text-mid' style='width: 25%;'>Initial IV Bolus</td><td class='custom-success-lgtbg text-mid' style='width: 25%;'>Follow-On IV Infusion</td></tr><tr class='white-bg'><td rowspan='2' valign='middle' class='text-mid'>&le; 5 mg</td><td>&lt; 8 hours or unknown</td><td>Low dose</td><td>400 mg at a target rate of 30 mg/min</td><td>4 mg/min for up to 120 minutes</td></tr><tr class='white-bg'><td>&ge; 8 hours or unknown</td><td>Low dose</td><td>400 mg at a target rate of 30 mg/min</td><td>4 mg/min for up to 120 minutes</td></tr><tr class='white-bg'><td rowspan='2' valign='middle' class='text-mid'>&gt; 5 mg or unknown</td><td>&lt; 8 hours or unknown</td><td>High dose</td><td>800 mg at a target rate of 30 mg/min</td><td>8 mg/min for up to 120 minutes</td></tr><tr class='white-bg'><td>&ge; 8 hours</td><td>Low dose</td><td>400 mg at a target rate of 30 mg/min</td><td>4 mg/min for up to 120 minutes</td></tr><tr class='gray-bg'><td colspan='3'>If andexanet alfa is not available, administer PCC or aPCC</td><td colspan='3' class='text-mid'>50 units/kg IV<sup>§</sup></td></tr><tr class='gray-bg'><td colspan='3'>Consider activated charcoal for known recent ingestion (within 2-4 h)</td><td colspan='3' class='text-mid'>n/a</td></tr></tbody></table></div>",

        "B20179_Table5_HTML": "<div class='table-wrapper'><table class='table table-scroll' style='font-size: 1em' border='1'><thead><tr class='custom-success'><td colspan='6'><center><b>Factor Xa Inhibitator (rivaroxaban)</b></center></td></tr><tr class='custom-success-secondary'><td style='width: 40%;' colspan='3'><b>Reversal Stratergy</b></td><td colspan='3' style='width: 60%;'><b>Dosage</b></td></tr></thead><tbody><tr><td rowspan='5' class='gray-bg text-mid' style='width: 10%;' valign='middle'>Andexanet alfa <sup>&quot;¶</sup></td><td class='custom-success-lgtbg text-mid' style='width: 10%;'>Last dose of rivaroxaban</td><td class='custom-success-lgtbg text-mid' style='width: 20%;'>Timing of last dose</td><td class='custom-success-lgtbg text-mid' style='width: 10%;'>Low/High</td><td class='custom-success-lgtbg text-mid' style='width: 25%;'>Initial IV Bolus</td><td class='custom-success-lgtbg text-mid' style='width: 25%;'>Follow-On IV Infusion</td></tr><tr class='white-bg'><td rowspan='2' valign='middle' class='text-mid'>&le; 10 mg</td><td>&lt; 8 hours or unknown</td><td>Low dose</td><td>400 mg at a target rate of 30 mg/min</td><td>4 mg/min for up to 120 minutes</td></tr><tr class='white-bg'><td>&ge; 8 hours or unknown</td><td>Low dose</td><td>400 mg at a target rate of 30 mg/min</td><td>4 mg/min for up to 120 minutes</td></tr><tr class='white-bg'><td rowspan='2' valign='middle' class='text-mid'>&gt; 10 mg or unknown</td><td>&lt; 8 hours or unknown</td><td>High dose</td><td>800 mg at a target rate of 30 mg/min</td><td>8 mg/min for up to 120 minutes</td></tr><tr class='white-bg'><td>&ge; 8 hours</td><td>Low dose</td><td>400 mg at a target rate of 30 mg/min</td><td>4 mg/min for up to 120 minutes</td></tr><tr class='gray-bg'><td colspan='3'>If andexanet alfa is not available, administer PCC or aPCC</td><td colspan='3' class='text-mid'>50 units/kg IV<sup>§</sup></td></tr><tr class='gray-bg'><td colspan='3'>Consider activated charcoal for known recent ingestion (within 2-4 h)</td><td colspan='3' class='text-mid'>n/a</td></tr></tbody></table></div>"

    }
              